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                                                                    ABSTRACT 
TITLE 
APOA1 GENE POLYMORPHISM G–75A (rs 1799837) AND C+83T (rs 
5069) AND ITS ASSOCIATION WITH CORONARY ARTERY DISEASE 
Apo A1 shows a main part in preventing the evolution of atherogenesis which is 
the main causative event in Myocardial infarction(MI).A large number of 
genetic studies were conducted to find the association of various Apo A1 gene 
polymorphisms and susceptibility of MI in different populations. With this 
background, the candidate gene of this study is Apo A1gene at two Msp 1 
restriction sites G–75A transition in the promoter region and C+83T 
transition in the first intron. 
 AIM OF THE STUDY  
Aim of the study were, 
1. Is there any genetic polymorphism in Apo A1 gene at two Msp 1 
restriction sites G–75A transition in the promoter region and C+83T 
transition in the first intron in the studied population?  
2. To study the distribution  of the Apo A1 polymorphic allele   
3. To find the association between the above mentioned two Msp 1 
restriction sites with respect to MI & Plasma lipid profile. 
 
 
MATERIALS AND METHODS 
The study group included 52 patients who had documented MI and the control 
group included 52 age, gender and risk factor matched groups. Fasting venous 
blood was collected from each subject and estimations of Glucose, Urea, 
Creatinine ,Total cholesterol(TC) ,Triglyceride(TGL), HDL,LDL, Apo A1, Apo 
B estimations. Blood collected in EDTA coated tube was used for polymorphic 
studies.  
RESULT 
Fasting serum levels of TC,TGL,LDL ,HDL, Apo A1and Apo B and Apo B/ 
Apo A1 ratio were estimated . TC,TGL,LDL level were significantly higher in 
cases compared with controls. Serum HDL, apo A1 level was significantly 
lower in the cases than in the control group and that the serum apo B level and 
apoB/apoA1ratio in the cases was significantly higher than in the control group.  
The lipid variables compared across genotypes at two polymorphic site is as 
follows 
POLYMORPHIC STUDIES: 
I. The C+83T (FIRST INTRON) polymorphism reveals that ‘TT’ homozygous 
genotype was higher among cases and ‘CC’ genotype was seen more in 
controls, CT more or less equal among cases and controls. Genotype 
difference between cases and controls were statistically significant (p - 
0.006).  As far as frequency, ‘T’ allele was higher among cases (0.36) as 
compared to controls (0.13); and frequency of ‘C’ allele was higher among 
controls (0.86) as compared to cases (0.63). No statistically significant 
differences were observed between C allele and T allele carriers for any lipid 
variables other than HDL.   
II. For G-75A (PROMOTER SITE) polymorphism, genotypes across the cases 
and control reveals that ‘GG’ homozygous genotype was higher among cases 
and ‘GA’ genotype was seen more in controls, AA more or less equal among 
cases and controls. But the difference was statistically insignificant.  As far 
as frequency, ‘G’ allele was higher among cases (0.75) as compared to 
controls (0.69); and frequency of ‘A’ allele was higher among controls 
(0.30) as compared to cases (0.25).In GA genotype mean HDL,Apo A1 were 
high and low Apo B/Apo A1 ratio as compared to GG genotype. But no 
statistically significant differences were observed between G allele and A 
allele carriers for any lipid variables 
CONCLUSION 
 In this study T allele is significantly increased in cases compared to controls 
which implies that the presence of T allele present in C+83T (first intron) of 
the Apo A1 gene, might increase the development of MI. When compared 
across the lipid variables , no significant difference were obtained other than 
HDL, since various factors influences the Apo A1 gene expression. 
  In this study, no statistically significant differences were obtained across 
genotype as well as lipid variables in G-75A (promoter) region of Apo A1 
gene for the development of MI. 
KEY WORDS 
Myocardial infarction ,Apo A1, Apo B, HDL,LDL, Polymorphism ,Genotype , 
C+83T(first intron),G-75A(Promoter site), Lipid Variables. 
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INTRODUCTION 
Myocardial infarction(MI), the most imperative form of 
Ischaemic heart disease(IHD) is one of the major consequence of 
atherosclerosis. As on date coronary artery disease (CAD) is considered 
to be the largest single contributor to global mortality and it‟s been 
denoted as“true pandemic that respects no borders” (2009,World Health 
Organization) and is expected to dominate more morbidity and mortality 
trends in the days ahead .CAD is found be an invisible epidemic which 
is the major source of poverty and blocks the financial development of 
various nations. This growing invisible epidemic is accelerating at a 
striking pace where more number of people and their families and 
communities will be affected. 
It has been forecasted that by 2030 non communicable 
disease(NCD) would contribute for greater than 75% of  mortality 
worldwide. Of this, CVD itself will contribute for more number of 
deaths in low economic countries as compared with  infectious diseases 
including HIV/AIDS, tuberculosis, malaria, maternal , perinatal 
conditions, and nutritional disorders altogether .  
2 
 
  As the Human Genome Project study was completed ,this in turn  
helps us to identify the genetic, physical and Single nucleotide 
polymorphism(SNP) maps of the human genome and  this provides the 
opportunity to map and identify the susceptibility genes for not only 
single-gene (Mendelian) disorders , but also complex polygenic (non-
Mendelian) traits. The evidence is well distinguished for heritability of 
MI(the consequence of CAD), so it is well established  that the 
inheritance being one of the most important risk factor for this polygenic 
trait. 
The saying “complex trait” as such indicates interaction between 
genes and with environment , along with the complex inheritance  which 
is common and highly probabilistic in phenotypic manifestation as 
compared to “simple” Mendelian traits. The impact of genetic factors 
are more important, and recent research in this field has led to 
identifying candidate genes associated with elevated  risk of 
susceptibility for  MI.  
The Current study in genetic cause for MI is being unravelled at 
an accelerated pace. The future assessment of a person‟s lifetime risk for 
developing atherosclerotic vascular disease by genetic analysis 
,formerly an idea is now evolving into reality. These findings could help 
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in lifestyle modification and the choice and dosage of specific drugs. 
The best way to fight the burden of CAD is the preventive approach. 
The trends in CAD mortality has been projected to shift from 
infectious to NCD over the next few years .The most affected 
population would be the poorest in low & middle-income countries and 
this economic groups are going to be disproportionally affected , with 
incidence being equal in both men and women . At the household level, 
there is an ample evidence to ascertain that CAD and other NCD 
contribute to poverty due to tragic illness like MI leading  to high 
spending either through out of pocket expenditure or health policies 
spending by the government agency. 
At macro-economic level, CAD is found to place a huge affliction 
on the financial prudence of low and middle economic countries.NCD 
including CAD and diabetes mellitus (DM) are estimated to reduce the  
Gross Domestic Product in low and middle economic countries which 
results in low financial growth, as many people are expected to die 
below the average span of life. 
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People in low and middle economic nations die prematurely from 
CAD and other NCDs since  : 
1. Since these people have less access to affordable and proper 
medical facilities including early detection of diseases. 
2. More exposed to factors that contribute to risk events like MI, 
such as alcohol, tobacco.  
3. They predominantly do not have the benefit of access to various 
prevention programmes as compared with high economic group 
people. 
Asian Indians--living both in India and abroad is found to have 
highest rates of CAD in the world.  The CAD among Indians is usually 
more aggressive at the time of presentation compared with any other 
population . The overall impact is considered to be much higher because 
the CAD in Asian Indians affects the "younger" working class 
population which will affect dizzying economic boom ,for a developing 
country like India and to sustain this growth it should have a healthy 
populace. 
The effect of established, as well as novel, risk factors is 
multiplicative in an exponential manner. Occurrence of family history 
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has been established in NCD like Hypertension (HT), DM, and CAD 
suggests that genetic basis has to be explored .  
Various traditional, non-traditional and novel risk factors are 
involved in the development of coronary artery disease which on in due 
course  led to the development of dreadful complication, MI. The above 
mentioned risk factors has been ineffectual in completely predicting the 
progression  of atherosclerotic changes , suggesting that specific genetic 
predisposition should be taken under consideration. 
Lipoproteins are involved in the pathogenesis of atherosclerosis. 
Epidemiologic studies have established that , there exist an transposed 
relationship between  serum levels of high-density lipoprotein (HDL), 
apo A1
11.13
, the main component of HDL and the occurrence of CAD 
(antiatherogenesis), whereas low density lipoprotein (LDL) has been 
established as an proatherogenic factor.
8-10,52
 The competency of reverse 
cholesterol transport (RCT) depends on the functional ability of apo A1 
and to form mature HDL 
14,15 
by its capacity to promote cellular 
cholesterol efflux,  lipid binding function and  activation of  an enzyme 
lecithin cholesterol acyltransferase (LCAT).Also efficacy depends on 
interaction with precise receptors and lipid transfer proteins. In 
assessing the risk for CAD there is an ample evidence to suggest that 
FIG:1
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apo A1 particularly, ratio between apo B/apo A1 are strong predictors 
than HDL/LDL ratio
9-11
. 
There are several investigations that are useful after the disease 
has set in. Genetic analytic study will be the screening tool before the 
development of CAD. In future the genetic analysis may lead to the 
development of Gene therapy mechanism which could be useful in the 
treatment of CAD and for the prevention of MI and will provide more 
insight on the genetic basis of CAD, to the circumstances leading to the 
infarct. 
Various studies established relationship between genetic 
polymorphism in ApoAI-CIII-AIV gene cluster and its association with 
variation in the levels of Triglycerides, HDL , Apo A1 levels , 
premature atherosclerosis, MI and CHD in different populations .
2,3-7
The 
ApoAI-CIII-AIV gene cluster approximately fifteen  kb size and is 
found on chromosome 11q23.3
1
This Closely placed gene complex 
which evolved from the same evolutionary sequence are thought to have 
significant role in lipid and lipoprotein metabolism.
2
 Genetic variation in 
this gene cluster will affect the gene expression in the hepatocyte as well 
as in the intestinal epithelial cells. 
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The purpose of my study is to explicate the relationship between  
two SNPs in the Apo A1,11q 23.3, namely the G-75A (Promoter region) 
and C+83T (First intron)with Myocardial infarction which is the sequel 
of CAD 
REVIEW OF LITERATURE
 
MI results in group of closely related syndromes generically 
designated as Ischaemic Heart Disease (IHD). Atherosclerotic  coronary 
arterial obstruction contributes more than 90% of MI. Hence it is termed 
as CAD or CHD. Onset of coronary atherosclerosis begins during 
childhood/adolescence and IHD is the late manifestation of this 
progressive events. 
CLINICAL MANIFESTATION OF IHD
84
: 
 MI 
 Angina Pectoris 
 Chronic IHD with heart failure 
 Sudden cardiac death 
 
 
FIG : 2 HISTOGRAM REPRESENTS THE  PROJECTED 
TRENDS&EXPECTED SHIFTS OF  COMMUNICABLE TO NCD 
ACROSS LOW,MIDDLE AND HIGH INCOME GROUPS OVER THE 
NEXT FEW DECADES. 
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EPIDEMIOLOGY OF CARDIOVASCULAR DISEASE(CVD)  
 According to global burden of disease survey (GBD)
34  
the 
estimated mortality in India with CHD was 1.6 million in the year 
2000.With the same trend being continued its estimated that in 2008 
,17.3 million people died due to CVD, which accounts for 30 percent of 
all global deaths. Out of the total mortality reported 7.3 million were 
due to CHD and 6.2 million due to stroke. It is predicted by the year 
2015, approximately 64 million cases of CVD are likely, of which 
nearly CHD cases accounts for 61 million. (the remaining would 
consists of  stroke, rheumatic heart disease and congenital heart 
diseases). Mortality from this cluster of diseases are anticipated to hit at 
a staggering rate of 3.4 million. Its alarming that by the time 2030 total 
number of people who will die from CVDs, which constitutes mainly 
heart disease and stroke, will increase to reach 23.3 million
21 
 There is a substantial unevenness in the shape and magnitude 
subsequently from 1950s with respect to mortality drift of CHD across 
various countries in the globe. Even among nations within the same 
topographical region, CHD mortality trends are not consistent.  
There were three CHD  trending mortality patterns were perceived :  
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1)  Rise-and-Fall pattern
26
-prominent in high economic growth 
countries (including Anglo-Celtic, Nordic and North western 
Continental European countries as well as in the United States of 
America and Australia). Here the mortality rates are elevated, 
peaked (in 1960s or early 1970s) and have fallen swiftly , by an 
average of about 50 percent. 
 2)  Rising pattern : CHD mortality rates have steadily increased 
which indicates an ongoing epidemic ;this type is distinguished in 
Eastern European and former Soviet countries, south east Asia 
where mortality trends is found to drastically increase at an 
alarming speed and in these countries the highest mortality rates 
were recorded.  
3)  Flat pattern
26
 : Notable in Japan and several European 
Mediterranean countries where CHD mortality rates have 
persisted relatively low and stable following the flat pattern 
(Beaglehole,1999; Mirzaei et al., 2009)
94
. 
In identifying the genomic basis of complex traits like CAD we 
are still in the early phase .From the panoramic angle of public health 
problem, no other polygenic trait is more vital than atherosclerotic CAD 
10 
 
and MI and it would be expected to be the number one cause of 
mortality worldwide by 2020. Linkage analysis, Genome wide 
association studies (GWAS)
33
 and specific genetic epidemiologic 
studies have, in cumulative , initiated to open up this field and it provide 
more understanding to the candidate genes underlying this common and 
most important condition. 
MYOCARDIAL INFARCTION 
EVOLUTION OF DEFINITION  
The World Health Organization (WHO) defined MI from clinical 
symptoms, abnormalities traced in ECG and serum/plasma enzymes 
levels. Now a days ,with the greater advancement in the availability of 
precise imaging techniques and more advancement in the clinical 
biochemistry which enables in detecting the cardiac marker enzymes, 
even when  a tiny focus of myocardial necrosis is present. Therefore, 
present clinical practices, health care delivery models, epidemiology and 
clinical trials would require a more specific definition and re-assessment 
of previous definitions of MI. 
Accuracy of detecting MI has been evolved over the years .Such 
evolution were occurred when glutamine oxaloacetic transaminase 
(GOT) was substituted with lactate dehydrogenase (LDH)
4
 and 
11 
 
advanced by creatinine kinase (CK) and the MB fraction of CK, i.e. 
CKMB activity and CKMB mass. The major  issues lies in the 
identification of MI, hence the European Society of Cardiology (ESC) 
along with American College of Cardiology(ACC)organised a 
consensus conference in 1999  to revise the definition of MI (published 
in the year 2000 ). 
Update of  2000 consensus document was made under  the 
headship of  ESC, ACC, and American Heart Association (AHA)  was 
summoned, together with World Heart Federation (WHF), a global Task 
Force committee, due to the substantial advancement in the diagnosis 
and treatment of MI over the years from the initial document was made. 
From various perspectives the Global Task Force embraces various 
number of working groups  in order to enhance the ESC/ACC criteria 
for the diagnosis of myocardial infarction to update the previous 
established criteria. 
The Task Force identifies that this explanation for the definition 
of MI will be exposed to diverse changes in the forthcoming days, as a 
result of scientific expansion. Therefore, its clearly understood that the 
definition is still not the final version for all time. The present definition 
will further undergo refinement in the expected days to come. 
12 
 
CRITERIA FOR DETECTING ACUTE MYOCARDIAL 
INFARCTION
16,17,18
 
The Acute MI is termed when there is evidence of myocardial 
necrosis in a clinical setting consistent with acute myocardial ischemia.  
The following are the criteria meets the diagnosis for MI:
66
 
Rise or fall of cardiac biomarker values (preferably cardiac 
troponin (cTn)] with at least one value above the 99th percentile upper 
reference limit (URL) and with at least one of the following: 
 Ischemia symptoms 
 Pathological Q waves traced in Electrocardiography. 
 New or recognised significant ST-segment–T wave (ST–T) 
changes  
 Occurrence of New left bundle branch block (LBBB). 
 ECHO findings of new loss/ regional wall motion abnormality of 
viable myocardium  
 Angiography or Autopsy findings of intracoronary thrombus  
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WORLD WIDE - CLINICAL CLASSIFICATION OF DIFFERENT 
TYPES OF MI
16,17,18
 
Type One : Spontaneous MI 
Type Two: MI  secondary to an ischemic imbalance 
Type Three: MI  resulting in death . 
Type Four a: MI related to per cutaneous coronary intervention 
(PCI)) imaging. 
Type Four b: MI related to thrombosis due to stent procedure. 
Type Five : MI related to coronary artery bypass grafting (CABG)  
PATHOLOGICAL DEFINITION: pathologically it can be defined as 
1. ACUTE - Acute MI is regarded by the recruitment of neutrophils at 
the affected focus. If the time interim is quite narrow e.g. six hours 
between the beginning of the infarction and death, minimal or no 
neutrophils may be seen in the affected focus
4
. 
2. HEALING–When the neutrophils are replaced by the recruitment of 
mononuclear cells and fibroblasts it characterises the MI at the healing 
stage. 
3. HEALED –Healed stage is represented by the presence of Scar tissue 
without cellular intrusion. The complete process leading to the 
14 
 
formation of scar tissue usually lasts for approximately five to six 
weeks
4
 . Reperfusion alters the microscopic and macroscopic features of 
the cardiac myocyte with the appearance of contraction band necrosis 
and large quantities of extravasated erythrocytes. 
CLASSIFICATION OF MI  BASED ON ELECTROCARDIOGRAPHIC 
FINDINGS
5
 
 ST elevation (STEMI) MI  
 NON STEMI  
Management practice guidelines helps in discerning STEMI and 
non-STEMI, as most of the epidemiological studies on which 
endorsements were made, but it does not discriminate transmural from 
nontransmural MI.  
CLINICAL FEATURES OF MI: 
Myocardial ischemia precedes the development of MI .             
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TYPICAL SYMPTOMS
18,27
:
 
 Various mixtures of discomfort in chest, epigastric region, upper 
extremity, mandibular area (with exertion or even at rest)  
  Ischemic corresponding including fatiguability or dyspnea . 
 Discomfort duration associated with AMI usually lasts for more 
than twenty minutes. 
 Diffuse discomfort- which is not positional/not localised /not 
affected by movement of the region. 
 Convoyed with diaphoresis, nausea or syncope. 
 Above mentioned symptoms are not precise for MI, this could be  
misdiagnosed and attributed to gastrointestinal, pulmonary 
,neurological or musculoskeletal disorders.  
OCCURANCE OF MI WITH ATYPICAL SYMPTOMS
27 
 Palpitations or Cardiac arrest 
 MI deprived of symptoms can occur in DM , Women, Elderly, 
Post-operative and critically ill patients. 
Atypical symptoms can occur when there is a increasing or 
decreasing  pattern of cardiac biomarkers, so cautious assessment 
of these patients is advised. 
16 
 
RISK FACTORS OF MI:
19,20,21 
 
INTERHEART STUDY CONDUCTED ACROSS 52 COUNTRIES IN 
SOUTH ASIAN COMPONENT  WITH THE KEY RESULT OF 
Nine risk factors that contribute to ninety  per cent of the population 
attributable risk (PAR) in men folk and ninety four per cent in 
womanhood category. 
 Compared to western population, deaths from AMI in south Asians 
were five to ten  years earlier. 
 South Asian men faces AMI 5.6 years younger than women.  
 Nine conventional risk factors30are lipid profile abnormality, 
smoking, HT, DM, obesity particularly abdominal, psychosocial 
factors, amount of ingesting fruits & vegetables, liquor consumption 
and regular physical activity altogether explains eighty six percent of 
the AMI risk in south Asians.  
 The most important risk factor in south Asians are atypically 
high ratio of Apo-B/ApoA-1 (higher in south Asians)
22
and 
smoking
30
cadre. 
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 Low literacy rate is associated with augmented risk of AMI 
worldwide. 
 South Asians have low protective lifestyle factors such as high 
vacation time , physical exertion and balanced ingestion of dietary 
fruits and vegetables than western population,  
  Significantly increased waist-hip ratio in south Asians. 
 Regular liquor consumption is not protective for AMI in south 
Asians. 
However occurrence of MI is pertained to higher age groups, the 
actual incidence depends on predisposing risk factors for 
atherosclerosis. Any risk factor when it is associated, actually doubles 
the relative risk of developing atherosclerotic CAD. 
Hyperlipidemia: 
Increased risk of coronary atherosclerosis and MI is associated 
with the rise in the levels of total cholesterol, LDL,  triglycerides or 
lower HDL level< 40 mg per decilitre. 
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Diabetes Mellitus 
DM patients either insulin-dependent or non–insulin-dependent , 
they are at greater risk of development and progression of CVD 
29
.DM 
not only increases the rate of evolution of atherosclerosis changes in the 
coronary arteries but it also affects the variability in lipid profile.  
Hypertension 
Either systolic or diastolic HT, is consistently associated with an 
augmented risk of occurrence of MI. This risk factor is significantly 
reduced with the intake of  appropriate drugs for elevated blood 
pressure. 
Tobacco Use 
Blood vessel damage can occur with the consumption of certain 
components of tobacco and tobacco combustion gases
58
. Atherosclerotic 
formation and progression occurs due to the body's response to this type 
of injury, thereby increasing the risk of MI. Smoking acutely increases 
thrombus formation by platelets.  
  
FIG : 3 MAJOR RISK FACTORS OF CAD 
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Male Gender:                                                                                                
Atherosclerotic vascular disease and MI incidence is higher in 
menfolk than women at all age groups
5
. With increasing age this gender 
difference in MI, however, narrows. 
Family History  
The source of familial coronary events is multifactorial and 
encompasses components, such as genetic mutations/polymorphisms 
and its interaction with various environmental factors (e.g. smoking, 
high-fat diet, exercise). Therefore  positive family history of premature 
coronary disease increases one‟s risk of developing atherosclerosis and 
MI. 
PROOF OF ASSOCIATION BETWEEN PREDICTIVE VALUE 
OF APO A-I , B AND CAD BY  FOUR RECENT PROSPECTIVE 
STUDIES
83 
1. The Quebec Cardiovascular Study -  this was the  first prospective 
study to show that elevated serum levels of apo B remained as an self 
determining risk factor for predicting ischemic coronary events and it 
has been determined that this association is higher in men with 
appropriate levels of LDLc.  
20 
 
2. AMORIS11 (Apolipoprotein-related Mortality Risk Study) - showed 
the apo B/apo A-I ratio was the distinct variable that was more 
strongly associated with higher risk of developing fatal MI, as 
compared with other lipid ratio‟s . 
3.  INTERHEART84study –when compared with several conventional 
risk factors like smoking, HT, DM, stress, obesity particularly 
abdominal and regardless of other variables like gender, age and 
ethnicity,  the ratio of apo B/apo A-I was more sturdily associated 
with predicting MI . 
4. MONICA/KORAstudy - The main findings of this study was the 
strong direct association between serum levels of apo B and risk of 
developing MI, whereas reciprocal relation exists with apo A-I levels 
and development of MI. However, even after adjustments to age, 
body mass index, smoking, DM and HT, the multivariate analysis 
showed ratio of apo B and apo A1was strongly allied with the risk of 
MI.  
Prediction of cardiac risk is attributed to increased apo B levels in 
some studies and in other studies it has been due to diminished Apo AI 
levels. But according to literature its evident that the balance between 
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atherogenic and antiatherogenic factors which is echoed by the ratio of 
apo B/apo A-1, represents an additional and important risk prediction 
parameters for CVD, and of now it is considered a better indicator when 
compared to lipids, lipoproteins and traditional lipid ratios. 
PATHOGENESIS 
  When there is diminished blood supply to the heart, myocardial 
ischemia results 
94
, if it exceeds a critical threshold and the  capacity  to 
maintain the normal function and homeostasis with the defect in 
myocardial cellular repair mechanism
18
, MI occurs. Ischemia at this 
acute threshold level for a prolonged duration, results in irrevocable 
myocardial cellular damage or necrosis. Increased myocardial metabolic 
demand, reduced provision of oxygen and nutrients to the myocardium 
through the coronary artery circulation, or both contributes critical 
myocardial ischemia. Superimposed thrombus on an ulcerated or 
unstable atherosclerotic plaque, it occludes the coronary circulation 
which then interrupts the supply of myocardial oxygen and nutrients. MI 
can also be precipitated when more than seventy five percent fixed 
coronary artery stenosis associated with coronary vasospasm caused by 
atherosclerosis or a dynamic stenosis also limits the supply of oxygen 
and nutrients.  
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Myocardial metabolic demand is increased in conditions like 
dissipation of physical exertion, HT (severe type- including forms of 
hypertrophic obstructive cardiomyopathy)and extreme stenosis of aortic 
valve. In addition to that, other cardiac valve abnormalities and reduced 
cardiac output states also causes decreased mean aortic pressure, which 
precipitates MI.                                                                                                                       
Disruption in the vascular endothelium is the cause for most of 
the MI events. This disruption which ultimately results in unstable 
atherosclerotic plaque formation , that culminates in intracoronary 
thrombus leading to blockage in blood flow of coronary arteries. If such 
an blood flow block continues for more than twenty minutes, 
irrevocable myocardial cell damage and necrosis will occur. 
Over a period of years to decades atheroma initially starts as a 
fatty streak , then progress to full fledged atherosclerotic plaque. Lipid-
rich core covered over by fibromuscular cap are the two key 
characteristic features of the clinically expressed atherosclerotic plaque. 
The area where the structural stability of an atheromatous plaque is 
often lost is at the shoulder region (juncture of the fibromuscular cap 
and the vessel wall). Fibromuscular cap is weakened by the activity of 
matrix metalloproteases and the release of other collagenases and 
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proteases in the plaque, which results in plaque rupture. Endothelial 
disruption and fissuring or erosion of the fibromuscular cap can also due 
to hemodynamic forces applied to the arterial segment in addition to 
action of proteases. 
The myocardial necrosis originally starts in the endocardial area 
more distal to the coronary arterial supply. As the time duration is 
prolonged, the coagulative necrosis also enlarges, extending from the 
endocardium to the myocardium and eventually reaches the epicardium. 
The necrosis area then spreads laterally to watershed areas or collateral 
perfusion. After six to eight hour period of coronary block, most of the 
distal myocardium get necrosed. The extent of necrosis defines the 
magnitude of the MI. More striated cardiac muscle can be saved from 
irrevocable damage or death if the blood flow is re-established. 
The  three key determining factors of MI are : 1) Level of the 
block in the coronary artery 2) length of the obstruction period  and 3) 
Presence or absence of collateral circulation.  
STEMI : Complete blockade of coronary artery after plaque rupture 
results in STEMI . Most often this is due to the plaque that previously 
caused less than fifty percent occlusion of the lumen.                                                                                                          
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NSTEMI : Usually allied with greater plaque burden without complete 
blockade. This difference enhances the increased early mortality seen in 
STEMI and the ensuing equalization of mortality between STEMI and 
NSTEMI after one year. 
ATHEROGENESIS
 
The normal arterial wall consists three well-defined layers
24,25
:  
 Intima layer- is the subendothelium of vessel wall. 
 Media – it includes vascular smooth muscle cells(VSMC) 
 Adventitia- periphery of the vessel wall, composed of looser 
connective tissue 
 
 
 
NORMAL CORONARY ARTERY            ATHEROSCLEROTIC   
       CORONARY ARTERY                                                                                        
WITH THROMBOSIS 
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NORMAL ARTERIAL ENDOTHELIUM- BARRIER TO 
ATHEROSCLEROSIS:
24,25
 
 Repels cells and inhibits blood clotting 
 Surface which repels cells floating in plasma (including platelets)- 
strongly antithrombotic 
 Substances can penetrate endothelium either through junctions 
between the endothelial cells, or by transgressing the cells 
themselves.  
 An important function, controlled by the endothelium, is the 
ability to dilate (vasodilatation) and to constrict (vasoconstriction) 
and thus regulate tissue and organ blood flow 
KEY EARLY EVENT IN ATHEROSCLEROSIS :
 
 Is Damage to the endothelium   
 main components are: 1. Endothelial dysfunction 2. Lipid 
deposition, and 3. Inflammatory reaction in the vascular wall 
these three eventually result, not only in the formation of 
atherosclerotic plaques, but in the entire arterial wall remodelling 
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This  whole process in motion is maintained, by an intense cross-talk 
between endothelial cells, VSMC, and plasma-derived inflammatory 
cells, macrophages, and lymphocytes  
The cross-talk involves an array of chemokines, cytokines, and 
growth factors which cause attraction of cells to the sites of 
atherosclerotic lesions, induce cell migration, proliferation, apoptosis, 
and the excess production of extracellular matrix 
1. ENDOTHELIAL DAMAGE                                                                                
Initially the damage is functional , the endothelium becomes more 
permeable to lipoproteins which move beneath the endothelial layer, in 
the underlying intima. Also the normal endothelium loses its cell-
repellent quality allows inflammatory cells into the vascular wall. Later, 
the endothelium may become physically damaged, or even completely 
destroyed 
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2. LIPID ENTRY – KEY PROCESS IN ATHEROSCLEROSIS 
 
Dysfunctional endothelial surface expresses ADHESION 
MOLECULES (Selectins) 
 
Promotes adhesion  of monocyte(precursor of macrophages)& Tcells via 
VCAM ('rolling' interaction of cells with endothelium ) 
 
Adhered cells stimulated by the monocyte chemoattractant protein-1 
(MCP-1) 
 
Crosses the endothelium and lodges in the intima 
 
Monocytes transform into resident macrophages (By Monocyte colony-
stimulating factor (M-CSF) secreted by endothelial cells& VSMC) and 
produce reactive oxygen species and at the same time T lymphocytes 
also enter the vascular wall at this stage. 
 
LDL oxidation in the intima.  
Increased expression of macrophage scavenger receptors (scavenger 
receptor A, and CD36) 
 
 Hormone angiotensin also causes increased expression of VCAM-
1 and MCP-1 & Nitric oxide production decreases in the damaged 
endothelium. 
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3. FUNDAMENTAL ROLE PLAYED BY INFLAMMATION 
 The exit of monocytes and T lymphocytes from lumen and their 
activation in the intima are parts of the inflammatory response.                                                  
 Possibly  there is a molecular mimicry between the antigens involved 
in atherosclerosis and the exogenous pathogens 
 Such putative antigen(s) might be infectious agents, or molecules 
modified by reactive oxygen species. For instance, 
phosphorylcholine group found in the oxidized LDL is also a 
component of the capsular polysaccharide of bacteria.  
BOTH INNATE AND ADAPTIVE IMMUNITY INVOLVEMENT 
IN ATHEROSCLEROSIS 
 Innate immunity includes recognition by scavenger receptors A, 
CD36  
 Molecules which possess patterns encoded in immune memory bind 
to these receptors 
 They activate cells through, pathway involving the transcription 
factor  NF-κB.  
 T cells, involved in adaptive immunity, are present in both early and 
late atherosclerotic lesions.                                                                                        
 Finally, circulating IgG and IgM-type antibodies produced against 
modified LDL  
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ANOTHER  HALLMARK OF ATHEROSCLEROSIS 
HYPERCHOLESTEROLEMIA      
 Contributes to the induction of VCAM-1 and MCP-1                                         
 Smaller size lipoproteins, the remnants and the LDL, are the most 
atherogenic , partly since they enter the vascular wall more easily.                                  
 After leaving plasma, the LDL are modified in a way which 
enhances their potential to cause damage.  
 Enzymes such as lipoxygenases, myeloperoxidase, and NADPH 
oxidases present in the activated macrophages facilitate LDL 
oxidation                                
 Oxidized LDL expresses VCAM-1 and MCP-1.                                                                                              
 They are cytotoxic to the endothelial cells and they are mitogenic for 
macrophages.                             
 LDL 'driver' apolipoprotein, apoB100, once oxidized, binds to the 
scavenger receptors, but not subjected to regulation by the 
intracellular cholesterol level.                                                                                          
 Macrophages overloaded with oxidized LDL form foam cells. 
 Conglomerates of these cells are visible in the arterial walls as 
yellow patches ( fatty streaks) 
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 Dying foam cells release lipid that pools within the intima.  
 These lipid accumulation become centres of the atherosclerotic 
plaques 
STRUCTURAL CHANGES IN ARTERIAL WALL DUE TO 
MIGRATION & PROLIFERATION OF SMOOTH MUSCLE 
CELLS 
 All the above is accompanied by profound changes in the behaviour 
of VSMC.  
 VSMC stimulated by growth factors such as the platelet-derived 
growth factor , the epidermal growth factor and the insulin-like 
growth factor-1. 
 Migrate and proliferate toward the lumen of the arterial wall .  
They secrete  
 Adhesion molecules and  
 MCP-1  
As do the endothelial cells, it also secretes variety of cytokines 
and growth factors like interleukin-1 (IL-1) and tumor necrosis factor 
(TNF-α).  
 Importantly, activated VSMC also synthesize extracellular matrix, in 
particular collagen, which is deposited in the plaque.  
FIG : 4 FIGURE REPRESENTING MECHANISM OF 
ATHEROSCLEROSIS  
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 As a result, the normally ordered structure of the arterial wall 
becomes completely disrupted, and the forming plaque may protrude 
into the lumen of the artery, interfering with the flow of blood. 
ATHEROGENESIS 
COMPONENTS OF ATHEROMATOUS PLAQUE
37
 
 Centre composed of  - the foam cells and the lipid pool  
 Periphery is fibrous 'cap' over the lipid pool- formed by collagenous 
matrix secreted by VSMC which had migrated into the intima and 
contains VSMC themselves, macrophages, and T lymphocytes.  
Mature atherosclerotic plaque-The lipid pool and fibrous cap 
penetrates the arterial wall on one hand and on the other side 
obstructs the arterial lumen   CAUSING SEVERE MI 
Parts of the more advanced lesions may also become calcified. 
 
ATHEROSCLEROTIC PLAQUE GROW SLOWLY – SUDDEN 
RUPTURE  IS THE REAL DANGER: 
FIG : 5 EVOLUTION OF ATHEROSCLEROSIS TILL ITS 
ACUTE RISK EVENTS 
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PATHOLOGICAL HALLMARKS OF MI 
Most commonly documented in the infarct area supplied by the 
affected coronary arteries are 
 Lipid-rich atheromatous plaque rupture, 
 Haemorrhage inside the plaque and  
 Thrombus with in the lumen. 
 Thrombus formation can occur following endothelial disruption 
through activation of platelets through the coagulation cascade. 
Occurrence of large thrombus interrupting the coronary blood flow will 
result in MI. Genesis of occlusive intracoronary thrombus formation 
cannot be fully explained by atheromatous plaque rupture and thus 
further development of AMI.  In addition to a variety of hematologic 
disorders, the role of the platelet-derived mediators including TXA2, 
serotonin, ADP, platelet-derived growth factor, tissue factor  that 
promote an environment for thrombosis and vasoconstriction and the 
decreased  availability of the natural endogenous substances like EDRF, 
tissue plasminogen activator and PGI2 occurs. 
PGI2 released from vascular endothelial cells is extremely 
unstable and it inhibit platelet aggregation. HDL stabilizes PGI2 through 
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the function of ApoA-I, which resides on the surface of HDL molecules 
and identified as PGI2 stabilizing factor. Decrease in HDL-associated 
Apo A-I in patients with unstable angina and during the acute phase of 
myocardial infarction indicates that HDL plays an more effective role in 
preventing coronary atherosclerosis and intracoronary thrombus 
formation by stabilizing PGI2 in addition to the generally accepted 
biochemical property of HDL to prevent the accumulation of cholesterol 
by mobilizing free cholesterol from tissues or macrophages. There is 
also a PGI2 synthesis-stimulating factor in serum that has not yet been 
identified chemically. EDRF or nitric oxide provides another important 
regulating system in the vessel wall 
PROTECTIVE ROLE OF HDL IN MI 
HDL transport cholesterol centripetally (from the periphery to the 
liver). Nascent HDL particles are in the form of disk shaped consisting 
primarily phospholipid (principally of phosphatidylcholine) 
&apolipoproteins A, C, and E. As HDL accumulates cholesterol they are 
rapidly converted to spherical particles. 
HDL is a reservoir of apolipoproteins A,C,E : 
 The main apoproteins in HDL are apoAI and apoAII  
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 Serve as a circulating pool of apo C-II , it is transferred to  
chylomicrons and VLDL. Also Apo CII is an activator of an enzyme 
lipoprotein lipase. 
  Apo E –this lipoprotein is prerequisite for the receptor-mediated 
endocytosis of  Intermediate Density Lipoproteins and chylomicron 
remnants 
 Nascent HDLs are originally small ( no cholesterol) and then 
repetitively gain and lose cholesterol .When HDL size is compared 
with LDL particles , it is smaller and denser. 
 Surface of each HDL particle have small number of (e.g. 2 or 3) 
apoA1  particles and they contributes to nearly all plasma apoA1
23 
, 
vary substantially in size, cholesterol content and possibly in 
biological activity.   
 Participates in the metabolism of other particles Chylomicrons, 
VLDL and remnants through component exchange ,by exchanging 
apoproteins, phospholipid, triacylglycerol (TGL) and cholesteryl 
ester . 
  
FIG : 6 METABOLISM OF HDL 
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HDL uptake of unesterified cholesterol: 
 HDL particles takes up the cholesterol , immediately esterifies it by 
the glycoprotein enzyme phosphatidylcholine: cholesterol 
acyltransferase (PCAT).it is otherwise known also as LCAT and      
L- stands for Lecithin . This enzyme is secreted by the hepatocytes. 
 HDL comprises high concentration of phospholipids (PL). PL is an 
important solubilisers  of cholesterol , this constituent in HDL make 
it as an excellent acceptors of unesterified cholesterol . Acceptance is 
from both lipoproteins particles and from cell membranes. This trail 
of events is known as reverse cholesterol transport (RCT)      
 LCAT binds to nascent HDL, and is stimulated by apo A-I. LCAT 
shifts the fatty acid located at the second carbon of 
phosphatidylcholine to cholesterol thus yielding hydrophobic 
cholesteryl ester, which is impounded in the core of the HDL & 
lysophosphatidylcholine binds to albumin.  
 As the cholesteryl esters begins to accumulate in nascent HDL, 
initially it transforms to fairly cholesteryl ester–poor HDL3 and 
finally to cholesteryl ester–rich HDL2 particle, that carries these 
esters to the hepatocyte. 
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 Cholesterol ester transfer protein (CETP), synthesised in the 
hepatocyte  facilitates the transfer of cholesterol esters from HDL to 
TGL-rich lipoproteins in exchange for some of their TGL and 
apoproteins.  
REVERSE CHOLESTEROL TRANSPORT(RCT) 
 This process is carried out by HDL and its precursors 
79
 from 
peripheral tissues ( ex: artery walls). Small HDL particles (more 
numerous) carry only two molecules of apoA1 and few cholesterol 
molecules, despite large HDL molecules carry three molecules of 
apoA1 and more than 100 cholesterol molecules. Such HDL particles 
can transfer some of their cholesterol load to the TGL-rich precursors of 
LDL particles and elevated TGL levels accompany low HDL-C levels.  
 The independent impact of HDL-C (particular types of HDL particle) 
to MI risk is therefore best evaluated by their effects on the particles 
or their precursors. 
HDL MATURATION AND THE PROTECTIVE EFFECT AFFORDED  
BY APOA-I 
 Apo A-I engages the adenosine tri phosphate–binding cassette 
transporter A-1 protein (ABCA1) ,they retrieve the cholesterol from 
the peripheral cells,  macrophages and they are converted into 
discoid pre migrating HDL.  
FIG : 7 CETP ACTIVITY IN ATHEROSCLEROSIS 
 
 
FIG 8 : REVERSE CHOLESTEROL TRANSPORT 
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 Maturation of HDL is by the action of LCAT, forming HDL
3
 and 
eventually, large buoyant HDL
2
which is then taken up by the 
hepatocyte by engaging scavenger receptor B1 (SR-B1).  
  Rich quantity of enzymes  having antioxidant function (including  
paraoxonase 1-PON1) are normally found in HDL
3
 and to a reduced 
amount in HDL
2
.  
 Oxidized LDL have lipid hydroperoxides, they get attached to the 
vascular endothelium through the lipoprotein-like receptor and 
stimulates vascular endothelial cells (VEC) to produce MCP-1.The 
Apo A1 like amphipathic 18-amino-acid peptide 4F both retrieves 
lipid hydroperoxides from LDL and substitutes for ApoA-I in uptake 
of cholesterol by engaging ABCA1, thus protects endothelial cells 
from ongoing inflammation .  
ROLE OF LCAT IN CHOLESTEROL EFFLUX: 
 LCAT Contains 416 AA, 
Displays two activities: 
 Phospholipase A2 activity-hydrolyses the sn-2 fatty acid from 
phosphatidylcholine, and  
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 Acyltransferase activity:transfers the fatty acid to Free 
Cholesterol and forms Cholesterol ester. 
OTHER FUNCTIONS OF HDL 
 During bacterial infection type 1 interferon is produced ,this is 
prevented by HDL particle.  
 Chemokines, CCL2 (MCP-1) and CCL5 are produced in the 
atherosclerotic plaque, this might possibly be accountable for the 
recruitment of cells to the affected site , such process is inhibited 
by HDL. 
 Attenuation or inhibition of LDL oxidation,  
 Stabilises enzyme endothelial nitric oxide synthase (eNOS) , this 
in turn causes dilatation of vessels. 
 One of the fascinating feature of HDL is that it may promote 
insulin secretion by pancreatic islets  
70
 
HDL – AS AN ANTIINFLAMMATORY AGENT  
 HDL fixes to LPS, thus hinders its capacity to elicit signalling via the 
CD14/MD2/TLR4 complex
66
. 
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 Recent thought is that HDL or apoA-I binding to ABCA1 on chronic 
inflammatory cell , macrophages is anti-inflammatory. 
 One ancillary process is possibly due to lipid efflux is promoted, cell 
surface rafts gets reduced which leads to reduced signalling via 
TLR4 and possibly other TLRs. 
 Alternative mechanism seems to be due to promotion of an anti-
inflammatory phenotype in the macrophages by apoA-I mediated 
stabilization of ABCA1  resulting in the autophosphorylation of 
JAK2 and activation of STAT3 
66
. ApoA1 lessens the over all 
expression of pro-inflammatory cytokines (IL-1, IL-6, and TNFα) 
produced  by macrophages considered to be an autonomous action of 
the lipid transport activity of ABCA1 
AN ANTI OXIDATIVE ENZYME IN HDL- PARAOXONASE 
 This enzyme is primarily synthesised by the hepatocytes                                
 Circulates in association with APO A1 and HDL 
 They hydrolyse substrates such as arylesters, phosphate esters, 
and lactones including thiolactones. 
FIG : 9 
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 Inactivates lipid peroxides and hydrogen peroxide and thus it 
offers protection against oxidative stress . 
Individual mechanism by which HDL may apply this anti-
inflammatory action is because of  its carriage of enzymes, paraoxanase 
adept of cleaving oxidized Phospholipids and platelet activating factor 
hydrolase.  
PROMISING MECHANISMS OF THE  
CARDIOPROTECTIVE PROPERTIES OF APO A-I  
 Augmentation of RCT, cholesterol efflux from the cells40 
 Enriched paraoxonase activity 
 Diminution of oxidative stress,  
 LCAT activation 
 Improved anticoagulant activity  
 Elucidation of the biochemical pathways regulating apo A-I gene 
expression is indispensable to the development of novel therapies for 
preventing atherosclerosis
38 
  
FIG : 10 OVER VIEW HDL &APO A1 IN PREVENTING 
ATHEROSCLEROSIS 
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APO A1 PROTEIN 
cDNA clones of  Apo A1  gene was first isolated and 
characterised by  Breslow et al . 70% of the HDL protein mass is 
occupied by Apo A1 approximately and 15-20% is occupied by Apo A-
II. Proteomic study conducted recently shows the remaining portion of 
HDL protein mass is made of amphipathic proteins which includes 
apoCs, E, D, M, A-IV, paraxonase. Structural studies of HDL should be 
made on  apoA-1, initially, because it occupies the bulk portion of HDL 
particles. Serum ApoA1 level is 1.0-1.5 mg/ml and it is a relatively 
abundant plasma protein. Liver and small intestine synthesizes Apo A1 
as a preproapolipoprotein having 267 amino acid residue. Signal 
peptidase , at the time of translation cleaves 18 amino acid residues, the 
presegment and the product proapoA-I having hexapeptide prosegment 
which are in covalent linkage with the NH2 terminus of mature apoA-
I.ProapoA1 is then secreted into venous and lymphatic circulation and 
further endures extracellular posttranslational cleavage to  provide 
matured 243-residue apoA-I
37
.  
Apo A1 is a solitary polypeptide chain with 243 amino acid 
residues of recognised primary amino acid sequence ,28-kDa single 
polypeptide that lacks glycosylation or disulfide linkages. 
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  In vivo ApoA1 has multiple conformations, with metabolic 
interconversion between lipid-free - poor, partially lipidated and fully 
lipidated states, triggered by ambient lipid concentration .  
          Apart from the N-terminal 44 amino acids, sequence of Apo A1 is 
organised into eight α-helical segments composed of 22 amino acids 
separated by proline residues
71
 . ApoA-I sequence analysis shows it is 
composed of repeated amphipathic α helices having 11 of 22 residues is 
responsible for the protein‟s lipid-binding regions. Hydrophobic and 
hydrophilic residues in the α helices of Apo A1 occupies the opposite 
sides of the helical cylinders. Negatively charged residues projects from 
the centre while positively charged residues placed at the edges and 
hence polar helix face exhibits zwitter ionic character. Helical segments 
fulfill the structural role of apoA-I, rather by the organized tertiary 
structure. This explains how the lipoprotein α helices float on 
phospholipid surfaces similar to logs on water. 
 
Ajees .et.al first conveyed the crystal structure of lipid free human 
apo A1 to 2.4-angstrom resolution.
69
 They revealed APOA1 consists of  
N-terminal 4-helix bundle with a hydrophobic core and 2 C-terminal 
helices. Lipid free conformation is predominantly maintained by the N-
terminal domain. Hydrophobic patches formed by four leucines in the 
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N-terminal domain  initiates unravelling of this domain to lipid bound 
open configuration .Function of  C-terminal domain was expected to 
have lipid affinity and they are the sensitive trigger for the lipid-
mediated unravelling of the N-terminal domain. Tyrosine in Apo A1 is 
chlorinated and nitrated by myeloperoxidase and this in turn causes 
defect in ABCA1-dependent cholesterol efflux, which is an considered 
to be atherogenic risk factor. Only solvent accessible area (for 
chlorination and nitration) in APOA1 is tyrosine-192
73
.
 
The domain that is highly conserved and explains antigenicity 
(mature protein 1-98 residues)in Apo A1 is the N terminal domain and it 
is this domain which plays an important role in structure and function of 
this protein. The central and C-terminal domains show conservative 
substitutions between species. 
 
 Binding of lipids is by the N and C terminal domains of Apo A1-
important function of this protein  
 LCAT activation is by the central domain- suggests that evolution 
might have occurred parallel. 
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STRUCTURE OF LIPID-FREE APOAI : 
 Stability and solubility of ApoA1 in lipid free state is primarily by 
the α-helices organised in bundles near the N-terminal half (AA 44-
126) where they are loosely folded . 
 Lipid poor Apo A1 mobilises cellular free cholesterol and 
phospholipid , is by the unstable C-terminal half (AA190–243).This 
area provides stability to α-helical segment including self-association 
and lipid binding.  
 Function of the central region in the Apo A1molecule between 
residues 139–170 is  interaction with the N-terminal portions thus 
stabilizing the α-helical bundle in the  lipid-free state. 
  Negative potential field around apoA-I is responsible for the 
docking of lipid-free apoA-I with ABCA1. 
STRUCTURE OF LIPID-BOUND APOAI 
 Major stabilising domain is the C-terminal half in lipid bound state 
and it becomes more highly α-helical. 
 Protein lipid contacts is made by the rearrangement of helixes 
involved in protein –protein interaction in the N terminal of Apo A1 
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TERTIARY STRUCTURE OF APO A1  IN LIPID FREE 
&BOUND FORMS FOR DISCOIDAL LIPOPROTEINS :  
Two models were proposed for two apoA-I molecular arrangement 
with phospholipids. 
72 
I. In Picket fence model:  Individual molecule of apoA-I wraps 
around the HDL disc in an antiparallel fashion with little 
intermolecular interactions between adjacent alpha-helices. 
II.  Belt model:  Two antiparallel apoA-I particles are paired by their 
C-terminal alpha-helices, wrap around the lipoprotein, and are 
stabilized by multiple intermolecular interactions. Recent evidence 
supports the belt model. 
ApoA-I alpha-helices control lipid binding and association with varying 
levels of lipids. 
 LCAT activation domain : Clearly assigned to helix 144-165 with 
secondary contribution by helix 166-186.  
 Displacement of apoA-I helices by LCAT and presentation of the 
lipid substrates : By the lower lipid binding affinity of the region 
144-186 . 
FIG.11 LIPID FREE  - LIPID BOUND STRUCTURE OF APO A1 
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  No specific sequence has been found that affects diffusional efflux 
to lipid-bound apoA-I.  
C-terminal helices :  important for lipid binding and maintenance 
of HDL in circulation, interaction of lipid-free apoA-I with 
macrophages and specific lipid efflux. 
MECHANISM  BY  WHICH  CHOLESTEROL EFFLUX  IS 
MEDIATED BY APO A1: 
Desorption of free cholesterol from the plasma membrane is the 
rate limiting step in diffusional efflux 
Factors which influences Desorption depends on  
 Properties of the cell membrane 
 The cell type in which it occurs 
 Presence of diverse pools of cholesterol &their inter-exchange 
with the plasma membrane 
 Protein distribution of HDL(Ratio of apoA-I &A-II )  
 Key factor may be the lipid composition of acceptors.  
Cholesterol flux between lipoproteins and cells is influenced by 
Free cholesterol and phospholipid content of HDL. 
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ABCA1 RECOGNITION MOTIF ON APO A1
 
Prior to cholesterol acceptance it is the docking of Apo A1 with 
ABCA1
73
, this process is not sequence specific and these have proven in 
recent studies. Surface charge analysis reveals that there exists an 
interaction between apoA-I with ABCA1 and SR-B1. ABCA1 
recognition motif on apoA1 is the dominant two negative patches.         
C terminal patch which is hydrophobic in nature adjacent to negative 
charge cluster, is the site where ABCA1 interacts with lipoproteins. 
Aspartic acid and glutamic acid  at position seventy three and seventy 
eight respectively belonging to helix two, contributes to largest negative 
patch which is ≈28Å  apart from the hydrophobic patch on C terminal 
domain is the ABCA1 recognition motif, although it is not proved with 
certainty. Negative potential field is created by the preponderant 
negative charge. Important prologue to is interaction is the electrostatic 
attraction of apoA-I with positively charged regions of ABCA1
73
. 
SR-B1 RECOGNITION SITE ON APO A1
73 
SR-B1 has separate binding sites for both lipid free and HDL-
associated apoA-I. 
FIG.12  
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Synthetic peptides analysis point out that the hydrophilic face of 
apoA-I helices is recognized by SR-B1. The surface of apoA-I has 
various potential positively charged docking regions for attachment to 
SR-B1. Offloading of cholesteryl ester to the hepatocyte is facilitated 
through contact of HDL bound apoA-I with SR-B1, whose extracellular 
domain binds both HDL and LDL. 
COMPREHENSIVE VIEW OF POLYMORPHISM & APO A1 
GENE 
POLYMORPHISM
36
: 
Otherwise known as polymorphic allele. 
 Defined as the occurrence of natural variations in a chromosome, 
DNA sequence or gene without inflicting any adverse effects on the 
individual.  
 In general population it exist in fairly higher frequency. 
It could be of either single base/nucleotide pair variation (SNP) or 
it involves long stretches of DNA of which the first type is the most 
common one.  
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SINGLE NUCLEOTIDE POLYMORPHISM 
 Alternative term “snips”. 
 Most of the SNPs have no issues on health or development. 
 On an average occurrence of SNPs in DNA is  1 / 300 nucleotides. 
SIGNIFICANCE BEHIND SNP STUDY 
 SNPs as biological pointers, it helps inventors to locate candidate 
genes that are linked with disease.  
 Genes function can be affected if SNPs occur inside a gene or in a 
regulatory region proximate to a gene.  
 Disease that run through families can be traced using SNPs. 
 Susceptibility to toxins , particular diseases and person‟s reaction to 
certain medications can be predicted by SNPs 
 Future scope of SNPs study is its association with complex diseases 
such as heart disease, diabetes, and cancer. 
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APO A1 GENE DESCRIPTION AND ITS REGULATION 
The reason behind why the Asian immigrants and Indians in 
urban area are at increased risk of developing MI is not yet clear. To 
understand the wide range of genetic/epigenetic influences on CAD
30
 
requires systematic and comprehensive study. Holistic approaches are 
needed to find the multiple factors (including genetic and environmental 
)behind the atherosclerosis, which eventually leads to MI.
26-29
 Wide 
variety of candidate genes was investigated behind the evolution of 
CAD
26-28
 which includes APOE, APOB,  LPL,  iNOS,  ACE,  COX2,  
CD14,  P-Selectin, ESelectin, MTHFR, PON1, TNFα . Only few studies 
on these genes have come out with promising signals to play a role in 
CAD. 
HGNC APPROVED GENE SYMBOL: APO A1Apolipoprotein A-I 
Short name=Apo-AI; ApoA-I 
Alternative  name : 
Apolipoprotein A1
 
Cleaved into the following 2 chains: 
1. ProapolipoproteinA-1  
short name=proapoA1 
2. Truncated apolipoprotein A-1 
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Taxonomy ID: 9606 (NCBI) 
Gene ID: 335 
Genbank  common  name: human 
Inherited  blast  name: primates 
Gene Type  :  Protein Coding 
Rank: species 
Authority: Homo sapiens Linnaeus,175 
CYTOGENIC LOCATION 
 
Ensembl cytogenic band : 11q 23.3 
Entrez gene cytogenic band: 11q 23- q24 
HGNC cytogenic band: 11q23-q24 
Exon count: 5 
Annotation release (current) : 106 
                            (previous)   : 105 
Genomic coordinates:  
(GRch38):11:116,835,751-116,837,950 
(GRch37):11:116,706,466-116,708,337 
Approximate molecular weight of 28.1 KDa 
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APO A1, CIII & AIV GENE COMPLEX - FROM COMMON 
EVOLUTIONARY PRECURSOR 
   The APOAI gene is coded on the chromosome 11 along with APOCIII 
and A IV genes. The APOA1-CIII-AIV genes are interlinked
32-35  
and 
this cluster is approximately fifteen Kb. Transcription of Apo C-III gene 
is in the reverse direction to Apo A-I &A-IV. Foot-to-Foot orientation is 
seen with APOA1 and CIII genes(3-prime end of APOA1 is trailed after 
an break of about 2.5 kb by the 3-prime end of APOC3)
1
.Clusters that 
contains APOA1-CIII-AIV genes thought to have been evolved from the 
same ancestral sequence, has its  dominant role in metabolism of lipid 
and lipoproteins. Apo A1 & Apo CIII has three introns , apo A IV has 
only two introns. Intron interrupting the 5‟ noncoding region of mRNA 
of Apo A1 & Apo C III is absent in Apo AIV .Any genetic variation 
within this gene cluster will have a significant influence on the hepatic 
& intestinal regulation of ApoAI-C-III -ApoA-IV gene expression. 
Amino acid  sequence analysis studies on apoproteins A-I, A-II, C-I, 
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and C-III says that they all would have derived from a common 
evolutionary predecessor. Apo A1 gene after its separation was 
stretched out by internal gene duplications. This contributes to six 
homologous 22-amino-acid long structures which inhabits most of the 
COOH-terminal half of the apo A-I polypeptide.  
 
 
 
 
APO A1 GENE DESCRIPTION: 
 Apo A1 gene is interposed by three intervening sequences (IVS) ,  
IVS-1, IVS-2, and IVS-3 happening in the 5'noncoding region of apo 
A-I mRNA, the mRNA sequence coding  for the signal peptide of 
apoA-I,
39
 and the sequence coding for the mature protein, 
respectively. 
 The existence of interposing sequences in the DNA region coding for 
the signal peptide, proposes that introns may have aided at some 
initial time to bring different exons together. 
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  Finally,the  polyadenylation signal and its sites of apo A-I mRNA 
are located 36 bp and 55 bp, respectively downstream from the TGA 
terminator of the apo A-I gene .  
 The coding region of the mature apo A-I mRNA, AUG initiator and 
UGA terminator offers the complete amino acid structure of the 
primary translation product of apo A-I mRNA.  
 Proteolytic cleavage between the amino acids at positions -1 
(glutamic acid) and + 1 (aspartic acid) is required for the conversion 
from Proapo A-I to mature apo A-I . 
 The sequence "TATA" (TATA box) has been perpetually found 25-
30 bp upstream of the mRNA start sites of many eukaryotic protein 
coding genes and appears to play a role in the elevation of 
transcription. 
DEFECTS IN APO A1 GENE ARE ASSOCIATED WITH HDL 
DEFICIENCIES 
 Tangier disease - Either due to an alteration in the coding region 
around the glutamine (- 1)-aspartic acid (+ 1)site of apo A-I gene 
or to a different mutation that affects the conversion of proapo A-I 
to mature protein
1
 
 Systemic non-neuropathic amyloidosis.  
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APO A-I GENE REGULATION 
APO A1 gene has been used as a model for the tissue specific 
expression in hepatocyte and intestine. The term tissue-specific genes 
are, in general, methylated other than the expressing tissue.
75It is the 5‟ 
region methylation status of ApoA1 gene determines the tissue specific 
activity. In all the tissues the 3‟-end flanking sequences are invariably 
hypomethylated due to an unusual characteristic CpG island at the 3‟-
end coding sequence. Regulation of Apo A1 gene expression is at the 
transcription level and is influenced by various factors like hormone, 
diet,developmental,physiological and various environmental stimuli. 
The promoter region of ApoA1 gene has TATA-like motif closer to the  
transcriptional start site .Alteration in hormonal or metabolic status can 
affect the expression of Apo A1 gene in a progressive or deleterious 
manner due to the existence several cis regulating elements 
Hepatocyte - specific Apo A1gene expression is chiefly governed  
by four families of liver-enriched transcription factors(TF): They are 
1)  Hepatocyte nuclear factor 3 (HNF3)  
2)  Hepatocyte nuclear factor 1 (HNF1)  
3)  The CCAAT enhancer binding proteins (C/EBP) family and  
4)  Various members of the nuclear receptor superfamily, such as 
hepatocyte nuclear factor 4. 
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Hepatocyte -specific genes are regulated by promoter/enhancer 
sequences containing closely spaced cis-acting elements on which 
various combinations of hepatocyte-enriched and ubiquitous factors 
assemble 
58
. The gene which codes for the apoAI, contains a powerful 
liver-specific enhancer present in the region between –222/–110 
nucleotide upstream of the transcription start site.Three cis-acting 
elements A(–214 to –192),B(–169 to –146)and C(–134to  -119) 
maintain the ApoA1 gene transcription in the liver with in the enhancer 
region .Sites A and C are bound by members of the nuclear receptor 
superfamily, including HNF4, ARP-1, RXRa and RAR/RXR 
heterodimers. Site B binds the hepatocyte-enriched factors HNF3ß, 
HNF3α and C/EBP . These factors although they bind independently to 
their cognate sites, they stimulate apoAI enhancer activity 
synergistically via conjoint recruitment of an uncharacterized 
transcriptional coactivator(s) 
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Synergy may result from cooperative binding of the transcription 
factors to their respective cognate sites. Alternatively,multiple 
secondary interactions of enhancer-bound factors with targets in the core 
transcription machinery could result in transcriptional synergy .The 
latter could occur directly, involving components of the RNA 
polymerase II-specific basal transcriptional factors (including the TATA 
box-binding protein-associated factors ;or indirectly, through adaptors 
and/or coactivators that serve to bridge the enhancer and core 
complexes. 
When both HNF-3 and HNF-4 occupy their binding sites, an 
intermediary factor that is present in hepatocytes is recruited to the 
enhancer and core transcription complexes , but not with either of them 
occupying their binding sites individually. By this way, this factor, in 
addition to simply being an adaptor molecule, could also function to 
integrate the signals regulating the primary TF (HNF-3 andHNF-4).This 
observation also adds another level at which apoAI tissue restriction is 
enforced. Thus, it is not expressed in some extrahepatic tissues because 
they lack the primary transcription factors, and in others, because the 
intermediary factor is absent.  
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REGULATION OF APO A-I GENE  – SUBJECT TO ALTERATIONS 
BY SEVERAL HORMONE & METABOLIC SIGNALLING 
PATHWAYS  
Its been noted various hormones stimulate apo A-I gene  
transcription. They bring apo A-I promoter action along with gene 
expression via proximal promoter elements resides between the 
nucleotides -235 and -144 (relative to the transcriptional start site, + 1) 
 Thyroid hormones &Retinoids – Directly through their nuclear 
receptor  which act on Apo A1 promoter
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 Estradiol – Inactivity of the estradiol-responsive transcriptional 
corepressor  RIP- 140, by the  interaction of HNF-3ß and the orphan 
nuclear receptor HNF-4 on the apo A-I promoter
58
,thus increasing 
apo A-I gene transcription. 
 Action of Glucocorticoids on Apo A1 gene  – They stimulate the 
binding of  transcriptional activator (HNF) - 3ß to the Apo 
A1promoter  
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APO A1 GENE FACTORS CAUSING TRANSCRIPTION 
REPRESSION: 
 HNF-4 
 Thyroid hormone receptor -Thyroid hormone receptor monomer 
fixes to a negative thyroid hormone response element (nTRE) 
existing in the 3‟ of the apo A-I gene TATA-box may destroy apo 
A-I gene transcription . 
 Insulin Response Core Element- (IRCE)Positioned between 
nucleotides - 404 and – 411 which is in 5‟ from the transcriptional 
start site. This element fixes to the ubiquitous TF, Sp1 is liable for 
the beginning of the apo A-I gene expression by insulin.  
 ARP-1 - apo A-I repressor protein-1 
ACTION OF INSULIN  ON THE APO A-I PROMOTER   
THROUGH AT LEAST TWO SIGNALING PATHWAYS 
Ras-raf and phosphatidylinositol 3-kinase (PI3-K), primary to 
activation of the mitogen-activated protein kinase (MAPK) and 
PKC(kinase C) kinases, correspondingly these pathways eventually 
target the TF Sp1
59,60
. Phosphorylation of Sp1 shows a vital role in apo 
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A-I expression by regulating the ability of Sp1 to bind the IRCE. 
Copious domains at Sp1 are targets for phosphorylation by multiple 
protein serine/threonine kinases.  
                            Sp1 has amino acid motifs recognized by both kinases.  
several potential phosphorylation sites for a variety of protein kinases 
including cAMP- or cGMP-dependent kinase, PKC, mitogen-activated 
protein kinase (Erk), casein kinase .Recent studies suggest that Sp1 is 
phosphorylated by Erk2  PKC , casein kinase  or PKA  The 
phosphorylation modification of Sp1 protein may lead to either an 
increase (e.g.Erk2) or decrease (e.g. casein kinase II) in its DNA binding 
activity.  The stimulatory effects of these kinases on apoAI promoter 
may require phosphorylation of Sp1
77
. GC-rich sequences can bind to 
more than one member of the Sp family. 
Sp1 phosphorylation at Thr355 activates the ApoA1 promoter. 
.           
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 Adrenalin and glucagon, activate hepatocyte adenylyl cyclase, 
and therefore potentially augment apoAI gene transcription, are 
traditionally thought of as agents that are “counter-regulatory”, in the 
case of apoAI, the effects of insulin would be in parallel or additive with 
the effects of glucagon and adrenalin. Similarly, by activating Gαq, 
hormones such as noradrenalin (α1-adrenoreceptor) and angiotensin-II 
(AT1 receptor) would activate PKC and add yet a further boost to apoAI 
expression.                                                       
EFFECT OF INSULIN RESISTANCE ON APO A-I EXPRESSION 
Reduced plasma concentration of HDLc and low plasma levels of 
apo A-I is one of the hallmark of insulin resistance or the metabolic 
syndrome X. It is contributed by augmented fractional clearance of HDL 
without an alteration in apo A-I production 
62,63
. Reduced 
responsiveness of the apo A-I gene to insulin perhaps reduces the apo 
A-I gene expression . 
APO A-I GENE EXPRESSION VS ALTERATION IN 
MICRONUTRIENTS & VITAMINS STATUS  
Either insulinomimetic/permissive effects on insulin action:  By 
minerals which includes chromium, vanadium, magnesium and zinc.
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ZINC DEFICIENCY :Transcription factors has zinc finger motif (in 
Sp 1) and hence it reduced control apo A-I gene expression
58,65
.This 
describes the organising effect of zinc ions                 
CONCENTRATIONS OF ZINC,  CHROMIUM OR VANADIUM 
AT SUPRAPHYSIOLOGICAL LEVEL 
Above mentioned minerals in increased concentration 
downregulates the apo A-I promoter activity. Vitamins having 
antioxidative action may disturb apo A-I gene expression.  oxidative 
state of a cell is also the trigger to the Apo A1 promoter activity. 
ENVIRONMENTAL VARIABLES AND ITS EFFECT ON APO 
A1 GENE EXPRESSION 
The most important environmental variables includes smoking, 
fat content in the diet, body mass index (BMI) and exercise . Oxidative 
stress caused by these environmental variables may act by selectively 
reducing liver apoA-I mRNA level
68
 increase in apoA-I mRNA 
degradation and a 2-fold rise in transcription of apoA-I gene. 
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UPREGULATION OF APO A1 GENE BY PEROXISOME  
PROLIFERATOR ACTIVATED RECEPTOR α (PPAR- α ) 
Vu dac et.al showed that Apo A1gene transcription is induced by 
interaction of PPARα with the positive PPRE which is present in the A 
site of Apo A1 gene promoter liver specific enhancer region. It also 
upregulates Apo A1, A II , HDLs surface phospholipid transfer protein 
and SR-B1,situated in hepatocyte outer membrane. Expression PPARα 
is high in brown adipose tissue and hepatocyte and to a smaller extend 
in Renal tissue, Cardiac &Skeletal muscle.  
          Three PPAR subtypes are :  α, γ and δ/β . They show a tissue-
specific expression and its functions overlaps with each other and even 
with that of other NRs .  
Some ligands such as polyunsaturated fatty acids and oxidized 
fatty acids are shared between the three subtypes. These ligands are able 
to infiltrate the cellular membranes and reach their target receptors in 
the nucleus.              
           Regulation of Apo A1 gene is by activation of PPAR-α80either 
directly by ligand or by ligand binding to RXR thus forming 
heterodimers.The natural RXR ligand, 9-cis retinoic acid, as well as 
synthetic RXR-selective compounds can trigger a PPRE– driven 
reporter gene in a PPAR-RXR-dependent manner .
55    
 
FIG.13 ROLE OF PPAR α IN FAT METABOLISM 
 
  
FIG.14 
 
  
64 
 
PPAR RESPONSE ELEMENTS 
Transcription is regulated by PPARs by forming heterodimers 
with RXRs. This receptor dimer is found to bind with REs occupying 
the 5'-hexamer.  
PPAR s –AN ADOPTED ORPHAN NUCLEAR RECEPTOR43,44,45 
PPARs comes under the family of adopted orphan nuclear 
receptors. Ligands have been identified for these orphan receptors and 
they are low-affinity dietary lipids like cholesterol derivatives and bile 
acids .They bind DNA as heterodimers with retinoid X receptor (RXR). 
Other members of this group are as follows: 
 Bile acids through farnesoid X receptor 
 Fatty acids oxysterols through liver X receptor 
 Constitutive androstane receptor & 
 Xenobiotics via pregnane X receptor 
COMPREHENSIVE VIEW OF ALL THE ABOVE MENTIONED 
TRANSCRIPTION FACTORS(NUCLEAR RECEPTORS) AND 
ITS MODULATION OF TRANSCRIPTION 
Nuclear receptors (NR) are TF, plenty of which are ligand 
triggered and they control the expression of precise target genes 
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involved in reproduction, development and general metabolism and is 
considered to be essential 
46
. Also some unexpected ligands like glucose 
for the liver X receptor and  dietary lipids  having low affinity for 
PPARs .When NRs are in the nucleus and attached to DNA, they curb 
transcription by recruiting coregulators and components of the basal 
transcriptional machinery. 
 
 
 
 
STRUCTURE OF NUCLEAR RECEPTOR 
NRs contain a highly preserved DNA-binding domain (DBD) 
&ligand-binding domain (LBD)  
The flexible N-terminal domain contains in most NRs  
 Ligand-independent transcription activation function (AF-1) 53.  .   
 N-terminal and linker (hinge) areas of NR proteins are not 
conserved.  
N TERMINAL CC TERMINAL 
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The interaction with CoAs and CoRs is controlled via helix. 
NRs bind DNA through zinc-finger motifs (zinc-finger C4-type) in their 
DBD. The DBD of all NRs contains two α-helices perpendicular to each 
other 
54
.  
  
 
 
 
 
One  α-helices is located behind the zinc finger and is inserted 
into the major groove of a  DNA sequence. Since the recognition helix 
is highly conserved throughout the NR family, almost all NRs recognize 
common DNA sequences 
TRANSCRIPTIONAL SILENCING – NR WITHOUT  LIGAND:  
             Recruits transcription-repressing factors known as CoRs to the 
target gene promoters
47. 
CoRs, such as nuclear corepressor (NCoR), 
recruits histone deacetylases (HDACs) , ATP-dependent remodelling 
complexes (ADCRs), such as the nucleosome remodelling and histone 
deacetylase complex (NURD), are also recruited by NRs in their 
repressive state to silence transcription by affecting chromatin structure 
in an ATP-dependent manner 
49
. Together these factors create a 
chromatin environment that actively reduces transcription. 
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TRANSCRIPTIONAL ACTIVATION – NR WITH  LIGAND:  
     When ligand binds to NR, it experiences conformational change, 
which then indicates to CoR abolishment and CoA recruitment . 
50 
CoAs 
can affect in different ways. Certain CoAs form a protein bridge 
between TFs and the basal transcription machinery allowing the 
communication between the distal enhancer elements and the proximal 
promoter
51
. TFs play an vital role in gene expression. 
INTESTINAL REGULATION OF APO A1 GENE
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Orphan nuclear receptors HNF-4 –when over expressed in 
intestinal cells induces Apo A1 gene expression. Expression of the 
apoAI gene in hepatocyte and intestine is organised by separate and 
distinct tissue-specific apoAI promoter regions, the activity of which is 
further induced by a distal enhancer located within the nearby apoCIII 
promoter.HNF-4 appears to play an important role in the enterocytic but 
not hepatic expression of the apoAI gene.  
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AIM OF THE STUDY 
Apo A1 shows a main part in preventing the evolution of 
atherogenesis which is the main causative event in MI . A large number 
of genetic studies were conducted to find the association of various Apo 
A1 gene polymorphisms and susceptibility of MI in different 
populations. With this background, the candidate gene of this study is 
Apo A1gene at two Msp 1 restriction sites G–75A transition  in the 
promoter region and C+83T transition in the first intron. 
Aims of the study were, 
1. Is there any genetic polymorphism in Apo A1 gene at two Msp 1 
restriction sitesG–75A transition in the promoter region and 
C+83T transition in the first intron in the studied population? 
2. To study the distribution  of the Apo A1 polymorphic allele 
3. To find the association between the above mentioned two Msp 1 
restriction sites with respect to MI & Plasma lipid profile. 
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MATERIALS AND METHODS 
 This study was carried out during the period March 2014 – 
August 2014.  It is a case- control study. The study population 
comprised of MI patients  admitted in Cardiology Intensive Care Unit, 
Kilpauk Medical College Hospital,  Chennai. All procedures concerning 
human subjects or patients were permitted by the Institutional Ethical 
Committee. 
STUDY POPULATION: 
CASES: 
The study group consisted of 52 
 Documented MI patients who got admitted in cardiology ICU 
 Older than 40 years  
 Either gender   
Patients were selected randomly who got admitted to the hospital and 
who  fulfilled the inclusion criteria.  
SELECTION CRITERIA FOR MI CASES INCLUDED: 
 Ischemia symptoms 
 Pathological Q waves traced in Electrocardiography 
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 New or recognised significant ST-segment–T wave (ST–T) 
changes   
 Occurrence of New left bundle branch block (LBBB). 
 ECHO findings of new loss/ regional wall motion abnormality of 
viable myocardium   
CONTROL SUBJECTS: 
The control group consisted of 52 numbers. 
Controls were recruited from outpatient clinic, Kilpauk Medical 
college. 
SELECTION CRITERIA  
 Age, Gender and Risk factor matched . 
 No history or clinical evidence indicative of CAD.  
EXCLUSION CRITERIA 
 Patients with Liver disorder. 
 Patients with Renal disorder. 
 Patients with Thyroid disorder. 
All cases and controls were subjected to detailed history with special 
reference to cardiovascular disease risk factors followed by complete 
clinical examination. 
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SAMPLE COLLECTION 
For the study, 5 ml of 12 hours Fasting Venous Blood was 
collected under sterile conditions from the ante cubital vein with explicit 
informed consent . 
From the cases, the sample was collected within 24 hours of the 
episode of MI. 
I. 3ml of blood was collected in plain vials and serum was separated 
after centrifugation at 3000 rpm for 10 minutes and alliquoted, into 3 
eppendorfs and stored at -20°C and were not thawed until the batch 
was analyzed for extended Lipid profile and routine chemistry 
examinations 
1. One aliquot was used for glucose, urea, creatinine and  
2. One aliquot was used for lipid profile estimations 
3. One aliquot was used for apoB and apoA1 estimations 
ESTIMATION OF FASTING SERUM GLUCOSE 
Method: Glucose oxidase peroxidase (GOD/POD) 
Kit Used: Erba 
Principle 
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        Glucose oxidase 
Glucose + O2 + H2O          Gluconic acid + H2O2 
                                              peroxidase 
H2O2 + Phenol+4AAP             Quinoneimine dye + 2H2O 
The intensity of pink colored Quinoneimine dye is proportionate 
to glucose concentration and was measured at 505nm. 
Reagent Composition 
Reagent1 : Enzyme reagent 
Glucose standard-100mg/dl 
Procedure 
To 1ml of working solution, 10μl of plasma was added and 
incubated at 37°c for 5 minutes and absorbance was measured at 505 
nm. 
Reference range 
Fasting plasma glucose: 70 –100 mg/dl  
ESTIMATION OF BLOOD UREA 
KIT : Accucare 
Method : UV - GLDH 
Principle : The test is performed as a kinetic assay in which the initial 
rate of the reaction is linear for a limited period of time. Urea in the 
sample is hydrolysed by urease to NH3 and CO2. The NH3 produced 
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combines with alpha-oxoglutarate and NADH in the occurrence of 
glutamate dehydrogenase to produce glutamate and NAD. 
  urease 
Urea+ H2O                                2NH4 + CO2 
                                           GLDH 
NH4
+
+NADH+H
+
 + oxoglutarate                      Glutamate + NAD
+ 
The initial rate of decrease in absorbance at 340nm is proportional 
to the urea concentration in the sample. 
Reagent 
Reagent I: buffer reagent 
Reagent II: enzyme reagent 
Urea standard: 50 mg/dl 
Mix 4 parts (4 ml) of buffer reagent with one part (1 ml) of enzyme 
reagent 
Procedure 
To 1 ml of the reconstituted reagent 10μl of serum is added 
andimmediately reading was taken at 340 nm. 
Reference Range 
Serum/ plasma : 15- 40 mg/dl 
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ESTIMATION OF SERUM CREATININE 
Kit used : ERBA 
METHOD : Jaffe's Method ,Initial rate 
Principle : Creatinine in alkaline solution reacts with picrate to form a 
orange-yellow compound. The colour is proportional to the 
concentration of creatinine in the sample when measured at 505nm. 
Reagent 
Reagent I : Picric acid 
Reagent II : Sodium hydroxide 
Creatinine standard: 2 mg/dl 
 Reagents were allowed to attain room temperature. Equal 
volumes of reagent 1 and reagent 2 were mixed , waited for 15 minutes 
before use . 
Procedure 
To 1 ml of the reconstituted reagent 100μl of the serum were 
added and  absorbance (A1 ) at 20 seconds after mixing was noted & 
final absorbance ((A2 ) at 80 seconds . 
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Calculation 
A = A2 - A1 
Creatinine (mg/dl) = 
Absorbance  of Test X concentration of 
standard ( mg/dl) 
Absorbance  of standard 
 
Reference Values 
Males : 0.9-1.3mg/dl 
Females : 0.6-1.1mg/dl 
ESTIMATION OF SERUM TRIGLYCERIDE 
Method : Enzymatic colorimetric method : GPO – PAP method 
Kit used : ERBA 
Principle : 
                                      Lipoprotein Lipase 
Triglyceride+H2O                                      Glycerol + Fatty acid 
                                      Glycerol Kinase 
Glycerol+ATP                                            Glycerol-3-Phosphate+ADP 
Glycerol-3-Phosphate Oxidase 
Glycerol-3-Phosphate +O2           Dihydroxyacetone Phosphate + H2O2                                                 
       
               Peroxidase 
2 H2O2+4Aminoantipyrine+DHBS                         Quinoneimine 
dye+H2O DHBS- 3,5-Dichloro- 2 hydroxy benzene sulfonate 
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The intensity of colour developed during the reaction is 
proportional to the triglyceride level in the sample and is measured at 
505nm. 
Procedure 
To 1 ml of the reconstituted reagent 10μl of serum & 10μl of 
standard added separately and read at 546 nm after incubation at 37°c 
for10 min. 
Triglycerides (mg/dl) = 
Absorbance  of Test X concentration of 
standard ( mg/dl) 
Absorbance  of standard 
 
Reference range 
Normal fasting levels -  < 150 mg/dl 
ESTIMATION OF SERUM TOTAL CHOLESTEROL 
Method : CHOD - PAP method 
Kit used : ERBA 
Principle : 
                                   Cholesterol esterase 
Cholesterol Ester+H2O                           Cholesterol + Fatty acids 
 
  Cholesterol Oxidase 
Cholesterol + O2       Cholestenone + H2O2 
 
Peroxidase 
H2O2+Phenol+4-Aminoantipyrine     Quinoneiminedye+ 4H2O 
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The concentration of cholesterol is proportional to the intensity of 
the red complex, which is measured at 505 nm. 
Procedure 
To 1ml of the reconstituted reagent, 10μl of serum & 10μl of 
standard was added separately and reading was taken after 5 minutes of 
incubation at 37°c. 
Cholesterol (mg/dl) = 
Absorbance  of Test X concentration of 
standard ( mg/dl) 
Absorbance  of standard 
 
Reference values 
Cholesterol: 150 to 200 mg/dl 
ESTIMATION OF HDL CHOLESTEROL 
Method : Direct enzymatic clearance assay 
Kit used : Spinreact 
Enzyme Reagent 1 
N,N bis(2-hydroxyethyl)-2-aminoethanesulphonic acid  100 millimoles , 
pH 6.6(25°C) 
2 Aminoethanosulfonic acid 
N-(2- hydroxyl-3- sulfopropyl)-3-5 dimethoxyaniline (HDAOS) 
Cholesterol esterase 
Cholesterol oxidase 
Catalase 
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Ascorbic oxidase 
Enzyme Reagent 2 
N,N bis(2-hydroxyethyl)-2-aminoethanesulphonic acid 100 mM ,pH 
6.6(25°C) 
2 Aminoethanosulfonic acid , 4- Aminoantipyrine 
Peroxidase, sodium azide ,surfactants 
Principle 
Two steps 
1. Elimination of chylomicron,VLDL- cholesterrol,LDL cholesterol : 
                              Cholesterol esterase 
Cholesterol Esters                            Cholesterol+Fatty acids 
 
   Cholesterol Oxidase 
Cholesterol + O2        4-Cholestenone + H2O2 
                         catalase 
2 H2O2                                        H 2O + O2 
2. Specific measurement of HDL cholesterol: 
Intensity of colour formed is proportional to HDLc concentration 
in the sample   
Cholesterol esterase 
Cholesterol Esters                            Cholesterol+Fatty acids 
                                Cholesterol Oxidase 
Cholesterol + O2                             4-Cholestenone + H2O2 
                                                Peroxidase 
2 H2O2 + HDAOS+ 4-AAP                         quinonmine +4H 2O 
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Procedure 
Blank - 300 μ l of reagent 1 was taken 
Test - To 300μl of reagent 1 add 5 μl of serum was added and incubation 
done at 37 °C for five minutes. 
Standard/Randox Controls - To 300μl of reagent 1 add 5 μl of calibrator 
was added and incubation done at 37°C for five minutes 
Absorbance (A1) of the samples & calibrator at 600 nm was noted, 
100μl of reagent 2 into blank, calibrator & sample was added  
Mixed and incubation done for 30 sec. 
Final absorbance (A2) of sample, calibrator, against the blank was noted 
Incubate for 150 sec , Read final absorbance (A2) 
Calculate the increase of the absorbance A = A2 - A1 
Calculations = 
Absorbance of  sample x calibrator 
concentration 
Absorbance of calibrator 
 
Reference value 
 Men Women 
Normal 35 – 50 mg/dl 45 – 60 mg/dl 
Low risk > 50 mg/dl >60 mg/dl 
High risk < 35 mg/dl < 45 mg/dl 
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ESTIMATION OF LDL CHOLESTEROL 
Method : Direct enzymatic colorimetric 
Kit used : Spinreact 
Reagent 1 
PIPES pH 7.0, 50 millimoles/L 
Piperazine – 1,4 bis(2-Ethanosulfonic acid)                                                            
TOOS 
N- ethyl-N- (2- hydroxyl-3- sulfopropyl)-3- methyl aniline  
Cholesterol esterase(CHE) 
Cholesterol oxidase (CHOD) 
Catalase 
Reagent 2 
PIPES Buffer   50  pH 7.0 
Piperazine – 1,4 bis(2-Ethanosulfonic acid)                                                             
4- Aminoantipyrine 
Peroxidase (POD) 
Sodium azide 
Principle 
Two steps 
1. Elimination of chylomicron,VLDL- cholesterrol, HDL cholesterol                               
   Cholesterol esterase 
Cholesterol Esters                            Cholesterol+Fatty acids 
                                Cholesterol Oxidase 
Cholesterol + O2                             4-Cholestenone + H2O2 
                                  catalase 
         2 H2O2                                        H 2O + O2 
  
81 
 
2. Specific measurement of LDL cholesterol: 
Intensity of color formed is proportional to LDLc concentration in the 
sample    
                              Cholesterol esterase 
Cholesterol Esters                            Cholesterol+Fatty acids 
                                Cholesterol Oxidase 
Cholesterol + O2                             4-Cholestenone + H2O2 
                                               Peroxidase 
2 H2O2 + HDAOS+ 4-AAP                         quinonimine +4H 2O 
Blank - Take 225 μl of reagent 1 
Sample - To 225 μl of reagent 1 add 3 μl of serum was added 
and incubate for 5 min at 37° C. 
Standard - To 225 μl of reagent 1 add 3 μl of standard was added 
and incubate for 5 min at 37°c. 
Initial absorbance A1 was noted. 
Add 75 μl of reagent 2 into blank, standard & sample 
Incubation done at 37°C for five minutes. 
Read the  final absorbance (A2 ) of sample, standard, against the blank 
at 600nm 
  
82 
 
 
LDL concentration  
   mg Dl 
= 
Absorbance of sample x Absorbance of 
standard  
Absorbance of standard 
 
Reference value 
Optimal - less than100 mg/dl 
Near optimal - 100- 129 mg/dl 
Borderline high - 130- 160 mg/dl 
High - more than160 mg/dl 
ESTIMATION OF APOLIPOPROTEIN B 
Method : Turbidimetry 
Kit Used : Spinreact 
Reagent : 
Diluent (R1) –Tris buffer 20 mmol/L, PEG, pH 8.3 & sodium azide 0.95 
g/dl 
Antibody (R2) – goat serum, anti-human Apo B, tris 50 mmol/L, 
pH 7.5, sodium azide 0.95 g/dl 
Apo B cal- 85 mg/dl. 
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Principle 
Turbidimetry 
Insoluble complexes formed by samples containing apo B mixed 
with anti-apoB antibodies. The change in absorbance caused by these 
complexes proportional to apo B levels in serum sample. 
Procedure 
1. Bring the reagents & photometer to 37°C. 
2. Assay conditions 
Wave length: 340 nm 
Temperature: 370C 
Cuvette light path: 1 cm 
3 . The instrument was adjusted to zero with distilled water 
4 . Pipette in to a cuvette 
Reagent R1 268 μl 
Sample or calibrator 2.3μl 
5 . Mixed & the absorbance (A1) after sample addition is noted. 
6 . 67 μl of reagent 2 to calibrator & sample was added, mixed & 
absorbance (A2) after two minutes after addition of R2 was taken. 
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Calculations 
Calculate the A2 – A1 of each point of the calibration curve and 
the values against the Apo B concentration of each calibrator was 
plotted. Apo B concentration in the sample was calculated by 
interpolation of its (A2 – A1) in the curve. 
Reference range 
Normal value – 69 – 105 mg/dl 
ESTIMATION OF APOLIPOPROTEIN A-1 
Method : Turbidimetry 
Kit Used : Spinreact 
Reagent : 
Diluent(R1) - Tris buffer 20 mmol/L,PEG, pH8.3 & sodiumazide 0.95 
g/dl 
Antibody (R2) – goat serum, anti-human Apo A-1, tris 50 mmol/L, 
pH 7.5, sodium azide 0.95 g/dl 
Apo A1 cal- 108 mg/dl. 
Principle 
Turbidimetry 
Insoluble complexes formed by samples containing apo A1 mixed with 
anti-apoA1 antibodies.the change in absorbance caused by these 
complexes proportional to apo A1 levels in serum sample. 
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Procedure 
1. Bring the reagents & photometer to 37 
°
c. 
2. Assay conditions 
Wave length: 340 nm 
Temperature: 37°c 
Cuvette light path: 1 cm 
3. Adjust the instrument to zero with distilled water 
4. Pipette in to a cuvette 
Reagent R1 268 μl 
Sample or calibrator 2.3 μl 
5. Mix & read the absorbance (A1) after sample addition 
6. 67 μl of reagent 2 to calibrator & sample was added, mixed & 
absorbance (A2) exactly 2 minutes after addition of R2 was taken. 
Calculations 
A2 – A1 of each point of the calibration curve was calculated and 
plotted the values against the Apo A-1 concentration of each calibrator 
dilution. Apo A-1 concentration in the sample is calculated by 
interpolation of its (A2 – A1) in the curve. 
Reference range 
Normal value : 122 – 161 mg/dl 
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I. For gene polymorphism studies fasting blood was collected in2 
ml EDTA coated tube. 
DNA EXTRACTION BY KIT METHOD: 
DNA MINIPREPARATION KIT: 
From helini biomolecules, Chennai. 
PRINCIPLE : 
On short incubation with proteinase K and in the presence of 
chaotropic salt,  cells are lysed  which immediately inactivates all 
nucleases. Nucleic acids in the cells , attach selectively to special glass 
fibres pre-packed in the Purefast purification filter tube. In a series of 
rapid 'wash and spin‟ steps it removes the contaminating cellular 
components ,thus bound nuclei acids get purified. A special inhibitor 
removal buffer was added , this allows even the application of 
heparinised sample material with 100U/ml of heparin. Finally low salt 
elution buffer  releases the nucleic acids from the glass fibre. This 
method eliminates the need for organic solvent extractions and DNA 
precipitation, allowing for rapid purification of many samples 
simultaneously. 
COMPONENTS OF THE KIT 
 Proteinase K solution 
 Lysis buffer 
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 Wash buffer 1 & 2 
 Isopropranolol 
 Elution buffer 
 Spin columns with collection tubes 
PROTEINASE K SOLUTION STORAGE: 
Solution were stored at -20 °. It is stable for at -20°C for upto 6 
months. 
PROCEDURE FOR DNA PURIFICATION: 
PRE-PROCEDURE STEPS: 
 Set water bath to 56°C 
 Warm elution buffer by keeping in water bath at 56°C 
 Prepare fresh 1.2 ml of 70% ethanol per sample. 
BLOOD / BUFFYCOAT: 
200 µl of blood or 200µl of buffy coat is added to a nuclease free 
1.5ml microcentrifuge tube and the following steps are carried out. 
1. 400µl of lysis buffer is added and 
2. Immediately mixed well by inverting several times (or gently 
vortex) 
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3. 20µl of proteinase K was added. 
4. Mixed by vortex for 10 seconds. 
5. 300µl of isopropranolol was added and mixed well by inverting 
several times. 
6. The sample was pipetted into the Purefast spin column and 
7. Centrifuged at 12,000rpm for 1min. 
8. The flow-through was discarded and the column is positioned 
back into the same collection tube. 
9. 500µl of Wash buffer I was added to the Purefast spin column 
and 
10. Centrifugation process for 1minute at 12,000rpm ,and the flow-
through is discarded and the column was  placed back into the 
same collection tube. 
11. 500µl wash buffer II was added to the Purefast spin column  
12. Centrifuged at 12,000rpm for one minute and the flow-through 
discarded the column was  placed back into the same collection 
tube. 
13. Do empty spin column centrifuge at 13000rpm for 2 minutes. 
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14. The flow-through was discarded and centrifuged for an 
additional. This step was essential to avoid residual ethanol. 
15. The Purefast spin column is transferred into a fresh 1.5 ml 
microcentrifuge tube. 
16. 60µl of the pre-warmed elution buffer  was added to the centre 
of Purefast spin column membrane.  
17. Take care not to contact the membrane with the pipette tip. 
Incubation pre warmed was  done at room temperature for two 
minutes and is centrifugedfor two minutes. 
18. The column was discarded and the purified DNA, was deep 
freezed at - 20° C. 
IDENTIFICATION 
Extracted DNA was identified by 1% agarose gel electrophoresis 
and comparison with a known molecular weight 1kb DNA (Lambda 
DNA) ladder .(Fig.15) 
  
FIG.15 EXTRACTED DNA 
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POLYMERASE CHAIN REACTION 
C+83T ( First Intron ): 
353 bp fragment of Apo A1gene was amplified using, 
 Forward primer:   
 5‟GGCCACGGGGATTTAGGGAGAA-3‟  
 Reverse primer: 
 5‟AGCTGGCTGCTTAGAGACTGCGA-3‟ 
G–75A (Promoter region):  
203 bp fragment of Apo A1gene was amplified using, 
 Forward primer : 
5‟-GCAGCTTGCTGTTTGCCCACTC-3‟ 
 Reverse primer : 
5‟-ACGCACCTCCTTCTCGCAGTCT-3‟  
(Primers for both the sites were designed by helini biomolecules) 
PRIMER RECONSTITUTION 
Primers were supplied in lyophilized form. Millipore double distilled 
water was used to prepare 100× concentrations i.e. 10 times the 
molecular weight of primer is the volume of water required to prepare 
100× concentrations which is 100µmolar solution. 
From this stock solution 10× concentration  was prepared as the working 
solution for PCR. 
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Both forward and reverse primer were spinned. 
For each polymorphic site TEA buffer was taken at a particular volume 
corresponding to the respective forward & reverse primer of 100 
pmol/µl . 
Inverted & Vortexed &mixed for 5 minutes & were centrifuged 
Eppendorf were named for both the polymorphic sites. 
180 µl of sterile distilled water were taken in the labelled Eppendorf. 
10 µl forward primer + 10 µl reverse primer were added 
200 µl of  reconstituted primers containing both forward &reverse 
primers for the respective polymorphic sites. 
MASTER MIX: 
2×PCR Master mix was used in the following composition 
Master Mix consists of basic components necessary for PCR. 
Reaction buffer consisted of Tris Hcl - pH 8.5 , (NH4)2SO4 ,MgCl2 – 3 
mM acts as catalyst &0.2%Tween 20 
dNTP‟ s were used in a concentration of 0.4 mM each. 
Taq polymerase in a concentration of 0.2 U/ µl 
Primers were used in a concentration of 10 pmol and DNA was used in 
a concentration of 200ng. 
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PCR was carried out in a reaction in volume of 20µL with the 
following components in the following manner, 
PCR master mix (contains gel loading dye)  – 10 µL 
Reconstituted  primers(for the site+83 ) – 5.0 µL 
DNA       – 5.0µL 
----------------- 
Total         -  20.0µL 
---------------- 
POLYMERASE CHAIN REACTION (PCR) 
Amplification of the extracted DNA was carried out in 
CYBERLAB SMART PCR-PRO, thermal cycler with the following 
cycling conditions 
STEPS IN PCR C+83T (first intron) POLYMORPHIC SITE: 
 Initial denaturation -  95° C /5min 
34cycles of 
 Cycle Denaturation   at 94°C for  30 seconds 
 Cycle Annealing        at 58°C  for 30 seconds 
 Cycle Extension        at 72°C  for 30 seconds 
 Final Extension         at 72°C for 10min 
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Amplified product – amplicons of 353 bp was identified by 2.5% 
agarose gel electrophoresis by comparison with a known 100bp DNA 
ladder. 
AGAROSE GEL ELECTROPHORESIS 
 PCR product was run on 2.5% agarose gel in a 25 mL agarose cast as 
follows: 0.625g of agarose was weighed and dissolved in 25 mL of 
TAE buffer with a pH of 8.0. 
 It was microwaved for 60 secs, cooled and ethidium bromide was 
added in a concentration of 0.5 µg/ml  from the stock of 10mg/mL  
added. It is poured into a cast and allowed to solidify for 45 min 
before it wss kept in the electrophoresis tank. 
 10µL of PCR product was loaded onto wells and 4µL of 100bp DNA 
ladder was loaded onto single well as a marker. It is run in an 
electrophoresis tank for 30min and visualized under UV illumination 
in e gel imager from life technologies.(Fig.16) 
  
FIG.16 PCR PRODUCT FOR C+83T (FIRST INTRON) 
 
  
94 
 
RESTRICTION FRAGMENT LENGTH POLYMORPHISM 
Apo A1 gene polymorphism at the site C+83T was spotted by 
digestion of the amplified PCR product with the MspI restriction 
enzyme trailed by run in 2.5% agarose gel electrophoresis. 
Restriction Digestion Procedure 
Tango buffer (1x)                             – 3 µL  for 100%MspI digestion   
Msp I  (10U/µL)    – 2.0 µL 
PCR   Product    – 10.0 µL 
Distilled  water                               – 15.0 µL 
--------------- 
Total                                                     30.0 µL 
                                                          --------------- 
 The entire procedure was carried out in ice. The contents were 
mixed thoroughly. 
 The eppendorf was then placed in a 37°C water bath for 1 hour . 
 Restriction digested product was subjected to 2.5% agarose gel 
electrophoresis for genotyping. 
Two restriction sites for Msp I with in 353 bp product. 
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RESTRICTION DIGESTED PRODUCT VIEWED BY RUNNING 
IN  2.5% AGAROSE GEL ELECTROPHORESIS  
PROCEDURE: 
•  Restriction Digestion product was run on 2.5% agarose gel in a 
25mL agarose cast as follows: 0.625g of agarose was weighed 
and dissolved in 25mL of TAE buffer with a pH of 8.0. 
•  It was microwaved for 60 secs, cooled and Ethidium bromide 
concentration 0.5 µg/ml  from the stock of 10mg/mL was added. 
It was poured into a cast and allowed to solidify for 45 min before 
it was kept in the electrophoresis tank. 
•  20µL of Restriction Digestion product was loaded onto wells and 
4µL of 100bp DNA ladder was loaded onto single well as a 
marker. It was run in an electrophoresis tank for 45min and 
visualized under UV illumination in e-gel imager from life 
technologies. (Fig.17) 
Analysis was done using 100 bp and 50 bp ladder. 
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C ALLELE-   have restriction site between 96-97 bp ( polymorphic 
site) as well as normal restriction site at  50-51bp . 
T ALLELE- destroy its site for restriction at position 96-97bp  
 CC (homozygous individuals)- will yield 257bp,46bp,50bp 
 CT (heterozygous individuals)- will yield 257bp, 46bp, 50bp,  
        303bp, 50bp 
 TT(homozygous individuals)- will yield 303bp,50bp 
FIG.17 RESTRICTION DIGESTION FRAGMENTS C+83T 
(FIRST INTRON) 
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G-75A POLYMORPHISM(PROMOTER REGION) 
I.EXTRACTED DNA SUBJECTED TO PCR AMPLIFICATION 
 POLYMERASE CHAIN REACTION 
PCR was carried out in a reaction in volume of 20µL with the following 
components in the following manner, 
PCR master mix (contains gel loading dye)           – 10 µL 
Reconstituted  primers (for the site -75)  – 5.0 µL 
DNA                                                              – 5.0 µL 
                                                                  ------------- 
Total                                                               20.0 µL 
                                                                   ------------- 
Amplification of the extracted DNA was carried out in 
CYBERLAB SMART PCR-PRO, thermal cycler with the following 
cycling conditions 
STEPS IN PCR FOR THE G-75 A(PROMOTER REGION) 
POLYMORPHIC SITE: 
 Initial denaturation       - 95°C /5min 
34cycles of 
 Cycle Denaturation       at 94°C for 30 sec 
 Cycle Annealing           at 55.9°C for 30 sec  
 Cycle Extension           at 72°C for 30 sec 
 Final Extension             at 72° C for 10min 
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Amplified product – amplicons of 203 bp was identified by 2.5% 
agarose gel electrophoresis by comparison with a known 100bp DNA 
ladder. 
AGAROSE GEL ELECTROPHORESIS 
•  PCR product was run on 2.5% agarose gel in a 25 mL agarose 
cast as follows: 0.625g of agarose was weighed and dissolved in 
25 mL of TAE buffer with a pH of 8.0. 
•  It was microwaved for 60 secs, cooled and ethidium bromide was 
added concentration 0.5 µg/ml  from the stock of 10mg/mL was 
added. It was poured into a cast and allowed to solidify for 45 min 
before it was kept in the electrophoresis tank. 
•  10µL of PCR product was loaded onto wells and 4µL of 100bp 
DNA ladder was loaded onto single well as a marker. It was run 
in electrophoresis tank for 30min and visualized under UV 
illumination.(Fig.18) 
  
FIG.18  PCR PRODUCT FOR  G – 75 A (PROMOTER REGION) 
 
  
99 
 
RESTRICTION DIGESTION OF THE PCR PRODUCTS 
RESTRICTION FRAGMENT LENGTH POLYMORPHISM 
Apo A1 gene polymorphism at the site G–75A (PROMOTER 
REGION) was spotted by digestion of the amplified  PCR product with 
the MspI restriction enzyme trailed by run in 2.5% agarose gel 
electrophoresis. 
Restriction Digestion Procedure 
Tango buffer (1x)                              – 3 µL  for 100%MspI digestion   
Msp I  (10U/ µL)                                – 2.0 µL 
PCR   Product                                  – 10.0 µL 
Distilled  water                                  – 15.0 µL 
                                                           --------------- 
Total                                                      30.0 µL 
                                                           --------------- 
 The entire procedure was carried out in ice. The contents were 
mixed thoroughly. 
 The eppendorf was then placed in a 37°C waterbath for 1 hour . 
Restriction digested product was subjected to 2.5% agarose gel 
electrophoresis for genotyping.(Fig.19) 
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LEFT END                           POLYMORPHIC SITE (G/A)                                  RIGHT END 
 1-------------------------------------------------------------------------------------------------------------------203 
103 bpfragment  100bp fragment 
 
 
 
1                         -                     103   104                      -                           203 
 
 
 
One restriction site for Msp I within 203 bp 
G ALLELE-   have restriction site between 103-104 bp (polymorphic 
site) yielding 103bp &100bp  
A ALLELE- destroy its site for restriction at position 103-104bp , so  
 GG (homozygous individuals)- will yield 103 & 100 bp 
 GA (heterozygous individuals)- will yield 203bp,103bp &100bp 
 AA (homozygous individuals)- will yield only 203bp 
Close 
1/1 
Msp I  
POLYMORPHIC 
restriction site 
FIG.19 RESTRICTION DIGESTION FRAGMENTS OF 
G–75A (PROMOTER REGION) 
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DATA COLLECTION 
PROCEDURES ANDINSTRUMENTS USED 
Data collection was done using standardized proforma. All the 
biochemical analyses were performed using automated (ROBONIK) 
clinical chemistry analyzer . 
QUALITY CONTROL 
All biochemical analyses were done using RANDOX calibrator 
(lot no 2351-562UE) and Controls (lot no 768UN level 2) for checking 
internal quality. The CVs of all the analytes performed were within the 
prescribed limits in accordance with CLIA. 
INSTRUMENTS USED FOR MOLECULAR ANALYSIS : 
1. Cooling microcentrifuge 
2. Millipore double distilled water 
3. Waterbath 
4. Ice flaker 
5. Minifuge 
6. PCR machine 
7. Electrophoresis apparatus 
8. Gel Doc 
CONFIDENTIALITY 
Explicit informed consent was acquired from all patients. 
Confidentiality and safety of the subjects were taken care.  
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RESULTS 
Master table1: gives the characteristics of MI patients along with their 
biochemical parameters Fasting Blood Glucose ,Urea , Creatinine, Total 
cholesterol(TC),TGL,HDL,LDL,ApoA1,ApoB,Genotype G-75A,C+83T 
Master table 2:  gives the characteristics of control group along with 
their biochemical Parameters,  Fasting blood sugar ,urea , creatinine, 
Total cholesterol,Triglyceride,HDL,LDL,Apo A1,Apo B,Genotype G-
75A,C+83T 
The mean for each parameter is also given in the table. 
STATISTICAL ANALYSIS 
1)  SPSS package was used for statistical analysis 
a) Pearson‟s correlation was used for univariate analysis. 
b) The groups were compared using Student‟s t test. 
c) p value of <0.05 is considered significant 
2)  Genotype frequency distribution between cases and controls 
werecompared with the x
2
 test for 2×2 contingency table. 
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3)  Analysis of variance (ANOVA) was used to know the relationship 
between fasting serum HDL, Apo B ,Apo A1,ratio of Apo B/Apo 
A1with the genotype distribution. 
 52 Acute Myocardial patients and 52 Age, Gender ,Risk Factor 
matched controls were analysed for genotype distribution of APOA1 
GENE POLYMORPHISMG–75A (PROMOTER REGION) AND 
C+83T (FIRST INTRON).The genotype distribution was studied with 
respect to as fasting serum levels of HDL, Apo B , Apo A1,Apo B /Apo 
A1 ratio. 
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TABLE:1 
BASELINE CHARACTERISTICS OF THE TWO GROUPS 
 
  
VARIABLE 
GROUP 
TOTAL 
NO OF 
PERSONS 
 
p VALUE 
AGE CASES(52) 53.77±8.34 
0.92 (NS) 
CONTROLS(52) 53.6 ±10.04 
GENDER 
DISTRIBUTION 
CASES(52) MALE 45 
1 (NS) 
FEMALE 7 
CONTROLS(52) MALE 44 
FEMALE 8 
H/O SMOKING CASES(52) YES 16 
0.257 (NS) 
CONTROLS(52) YES 10 
H/O 
ALOCOHOL 
CASES YES 17 
0.669 (NS) 
CONTROLS YES 14 
H/O CAD CASES(52) YES 8 
0.003 (S) 
CONTROLS(52) YES 0 
DM CASES(52) YES 24 
0.692 (NS) 
CONTROLS(52) YES 21 
HT CASES(52) YES 13 0.816 (NS) 
 CONTROLS(52) YES 11 
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 The mean total Age value of cases is 53.77 and controls is 53.60 
p=0.92(NS) 
 The  GENDER DISTRIBUTION in cases and controls were, 45 
males and 7 females in cases and 44 males and 8 females in controls,   
X 
2  
- 0.078 , p= 1.0 (NS) 
 The number of SMOKERS in cases were 16 and in controls -10 ,  X 2  
- 1.846, p= 0.257 (NS) 
 The number of ALCOHOLICS in cases were 17 and in controls -14 ,  
X 
2  
- 0.414 , p= 0.669(NS) 
 The number of persons with H/O CAD in cases were 8 and in 
controls -nil ,  X 
2  
- 8.667 , p= 0.006 (S) 
 The number of persons with H/O DM in cases were 24 and in 
controls -21 , X 
2  
- 0.353, p= 0.692(NS) 
 The number of persons with H/O HT in cases were 13 and in controls 
-11 , X 
2  
- 0.217, p= 0.816(NS) 
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TABLE 2 
COMPARISON OF AGE , BLOOD SUGAR ,UREA & 
CREATININE  BETWEENCASES AND CONTROLS 
VARIABLE GROUP TOTAL MEAN SD 
p 
VALUE 
GLUCOSE CASES 52 136.23 76.63 
0.43(NS) 
CONTROLS 52 124.94 70.58 
UREA CASES 52 30.17 26.20 
0.05(NS) 
CONTROLS 52 22.79 7.30 
CREATININE CASES 52 1.30 1.05 
0.01(S) 
CONTROLS 52 0.93 0.15 
 
 The mean GLUCOSE value of cases is 136.23 mg/dl and controls is 
124.94 mg/dl, p= 0.43. 
 The mean UREA value of cases is 30.17mg/dl and controls is 
22.79mg/dl, p=0.05. 
 The mean CREATININE value of cases is 1.30 mg/dl and controls is 
0.93; p-0.01 
  
BAR DIAGRAM SHOWINGCOMPARISON  BETWEEN CASES 
AND CONTROLS ON FASTING SERUM GLUCOSE ,UREA, 
CREATININE 
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TABLE 3 
COMPARISON OF SERUM TOTAL HOLESTEROL, 
TRIGLYCERIDE AND LDL LEVELS BETWEEN CASES AND 
CONTROLS 
VARIABLE GROUP TOTAL MEAN SD 
p 
VALUE 
TOTAL 
CHOLESTEROL 
CASES 52 197.42 57.05 0.005(S) 
CONTROLS 52 169.33 42.40 
TRIGLYCERIDE CASES 52 164.13 60.85 0.001(S) 
CONTROLS 52 128.90 44.52 
LDL CASES 52 118.52 43.50 0.03(S) 
CONTROLS 52 101.44 39.06 
 
 The mean TOTAL CHOLESTEROL value of cases is 
197.42mg/dl and controls is 169.33 mg/dl, p=0.005. 
 The mean TRIGLYCERIDE value of cases is 164.13 mg/dl and 
controls is 128.9 mg/dl, p= 0.001. 
 The mean LDL value of cases is 118.52mg/dl and controls is 
101.44mg/dl, p=0.03 
  
BAR DIAGRAM SHOWING COMPARISON  BETWEEN CASES 
AND CONTROLS ON SERUM TOTALCHOLESTEROL, 
TRIGLYCERIDE & LDL LEVELS 
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TABLE 4 
COMPARISON OF SERUM HDL, APO A1,APO B ,APOB/APO A 
RATIO BETWEEN CASES AND CONTROLS 
 
VARIABLE GROUP TOTAL MEAN SD 
p 
VALUE 
HDL CASES 52 48.54 12.74 0.000 (S) 
CONTROLS 52 63.08 13.80 
APO A1 CASES 
 
52 81.46 22.30 0.000 (S) 
CONTROLS 52 114.02 18.14 
APO B CASES 52 98.79 25.04 0.004 (S) 
CONTROLS 52 84.48 23.84 
APO B  
/APO A 
CASES 52 1.29 0.52 0.000(S) 
CONTROLS 52 0.74 0.21 
 
 The mean HDL value of cases is 48.54 mg/dl and controls is63.08 
mg/dl, p=0.000. 
 The mean APO A1 value of cases is 81.46  mg/dl and controls is 
114.02mg/dl, p= 0.000. 
 The APO B value of cases is 98.79 mg/dl and controls is 
84.48mg/dl, p=0.004. 
 The mean APOB /APO A1 RATIO value of cases is 1.29 mg/dl 
and controls is 0.74,p =0.0000 
COMPARISON  BETWEEN CASES AND CONTROLS ON 
SERUM  HDL , APO A1,APO B , APO B/ APO A1 RATIO 
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TABLE 5 
GENOTYPE DISTRIBUTION OF APO A1 C+83T (FIRST 
INTRON)IN MI CASES AND CONTROLS 
 CC (n%) CT(n%) TT(n%) 
CASES 
(n – 52) 
31 
( 59%) 
4 
(8%) 
17 
(33%) 
CONTROLS 
(n – 52) 
42 
(81%) 
6 
(11%) 
4 
(8%) 
TOTAL 
(104) 
73 
(70.19%) 
10 
(9.61%) 
21 
(20.19%) 
 
The GENOTYPE FREQUENCY were 
CASES : CC-59% , CT- 8%, TT - 33%. 
CONTROLS :CC- 81 % , CT- 11 %, TT - 8 %.  
This was found to be in Hardy Weinberg equilibrium, 
C Allele Frequency- Cases:0.63; Controls-0.86 
T Allele Frequency- Cases:0.36;Controls-0.13 
X
2
 value- 10.105, p value is 0.006 (S) 
  
PIE CHART SHOWING GENOTYPEC+83T (FIRST INTRON)                                                                                                      
DISTRIBUTION IN THE STUDY POPULATION 
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TABLE:6 
COMPARISON OF HDL, APO A1, APO B , APO B/APO A1 
LEVELS IN DIFFERENT GENOTYPES AT +83 BASE PAIRS 
INDIVIDUALLY 
In mg/dl CC CT TT p VALUE 
HDL 56.05 ±13.59 51.3±9.522 57.10±21.375 0.036 (S) 
APO A1 100.08±26.707 97.80±15.843 89.52±26.726 0.572 (NS) 
APO B 93.08±23.703 83.70±24.363 90.38±31.385 0.080 (NS) 
APO B / 
APO A1 
1.02±0.480 0.86±0.267 1.12±0.564 0.167 (NS) 
 
 The mean HDL value  across genotypes ,CC is 56.05mg/dl,  
CT-51.3 and  TT -57.10 with p= 0.036 
 The mean APO A1 value across genotypes ,CC is 100.08 mg/dl,  
CT-97.8 and TT –89.52 with p= 0.572 
 The mean APO B value across genotypes ,CC is 93.08 mg/dl,  
CT- 83.7  and TT – 90.38with p= 0.080 
 The mean APO B/APO A1 Ratio value across genotypes ,CC is 1.02,  
CT- 0.86 and TT – 1.12 with p= 0.167 
  
BAR DIAGRAM SHOWING GENOTYPE DISTRIBUTION AND       
SERUM LEVELS  HDL , APO A1 AND APOB 
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TABLE 7 
GENOTYPE DISTRIBUTION OF APO A1 G–75A (PROMOTER) 
 GG(n%) GA(n%) AA(n%) 
CASES 
(n – 52) 
30 
(58%) 
18 
(34%) 
4 
(8%) 
CONTROLS 
(n – 52) 
23 
(44%) 
26 
(50%) 
3 
(6%) 
TOTAL 
( n- 104) 
53 
(50.59%) 
44 
(42.43%) 
7 
(6.73%) 
 
REGION)INMI CASES AND CONTROLS 
The GENOTYPE FREQUENCY were 
CASES: GG -58% , GA- 34%, AA - 8%. 
CONTROLS: GG- 44 % , GA- 50 %, AA - 6 %.  
This was found to be in Hardy Weinberg equilibrium,  
G Allele Frequency- Cases:0.75; Controls-0.69 
A Allele Frequency- Cases:0.25;Controls-0.30 
X
2
 value- 2.522 , p value is 0.283(NS) 
 
PIE CHART SHOWING GENOTYPE DISTRIBUTION OF APO 
A1  G–75A (PROMOTER REGION) IN MI CASES AND 
CONTROLS 
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TABLE:8 
COMPARISON OF HDL, APO A1, APO B ,APO B/APO A1 
LEVELS IN DIFFERENT GENOTYPES AT  - 75 BASE PAIRS 
INDIVIDUALLY 
 GG GA AA p VALUE 
HDL 53.40±11.404 59.95±18.406 48.00±10.583 0.592 (NS) 
APO A1 95.42±23.891 100.91±29.479 95.43±17.803 0.263(NS) 
APO B 97.00±22.374 85.66±28.498 88.57±19.121 0.535(NS) 
APO B/  
APO A1 
1.11±0.542 0.93±0.419 0.95±0.247 0.390(NS) 
 
 The mean HDL value across genotypes ,GG is 53.40mg/dl,  
GA-59.95 and  AA – 48.00 with p= 0.592 (NS) 
 The mean APO A1 value across genotypes , GG is 95.42 mg/dl,  
GA -100.91 and AA– 95.43 with p= 0.263 (NS) 
 The mean APO B value across genotypes ,GG is 97.00 mg/dl,  
GA - 85.66 and AA – 88.57 with p= 0.535 (NS) 
 The mean APO B/APO A1 Ratio value across genotypes ,  
GG - 1.11,   GA - 0.93 and AA – 0.95 with p= 0.39 (NS) 
  
BAR DIAGRAM SHOWING COMPARISON OF HDL,APO 
A1,APO B  AND APO B/APO A1 LEVELS IN DIFFERENT 
GENOTYPES AT - 75 bp 
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DISCUSSION 
  Many epidemiological studies have established that increased 
levels of Apo AI are associated with reduced occurrence and severity of 
CAD
83
.
 
Several studies have analysed the possible involvement of 
genetic variations in the Apo A1- CIII-AIV locus in determining 
phenotypes and CHD. The methodology more widely used was the 
association of restriction fragment length polymorphisms (RFLPs) with 
lipids, lipoprotein, and apolipoprotein levels, and CHD. 
The hypothesis in the current study is to establish the relationship 
between two polymorphisms C+83T (FIRST INTRON) AND G–75A 
(PROMOTER REGION)in Apo AI gene with lipid profile and 
occurrence of MI. At both these sites single nucleotide replacements 
effect in loss of MspI restriction sites so that both polymorphic sites are 
detected with PCR and MspI digestion in a single run. Both nucleotide 
changes are at regulatory hot spots. The single nucleotide change at -75 
bp (promoter region) is found to be associated with altered apo AI 
transcription
81,82
and the base change at +83 bp(in the first intron )is 
found to alter either transcription or translation but the mechanism 
behind this has not yet been established 
82
. 
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This study aimed to look for individuals with the single nucleotide 
change at the above two mentioned sites are likely to have a reduced 
risk of developing MI. 
 The ApoAI-CIII-AIV gene cluster is approx 15Kb. Apo A1 gene 
has three introns . Apo A1 gene is disturbed by three intervening 
sequences (IVS) , IVS-1, IVS-2, and IVS-3
1
  in the DNA region codes 
for the signal peptide of Apo A1. APO A1 gene has tissue specific 
expression in hepatocyte and intestine. Methylation status of the 5‟-end 
of the apo-AI gene is indicative of its tissue-specific activity and 3‟-end 
flanking sequences of the gene are invariably hypomethylated in all 
tissues due to an unusual characteristic of the presence of a CpG island 
at the 3‟-end coding sequence. The DNA region between the nucleotides 
- 256 and - 41 upstream from the transcription start site of the human 
Apo A1 gene is essential and adequate for maximal expression.
76
 
The apo A-I gene promoter contains a TATA-like motif close to 
the (25-30 bp upstream) transcriptional start site. Also Apo A1 gene is 
regulated by promoter/enhancer sequences containing closely spaced 
cis-acting elements on which different combinations of hepatocyte-
enriched and ubiquitous factors assemble in the cis regulating elements 
in either a positive/negative manner in response to changes in the 
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hormonal or metabolic status, diet and environmental factors in the liver 
and intestine. 
  In hepatocytes,  ApoAI gene transcription is maintained by three 
cis-acting elements, sites A (–214 to –192), B (–169 to –146) and C (–
134 to –119), within the enhancer. Sites A and C are bound by members 
of the nuclear receptor superfamily. Site B binds the hepatocyte-
enriched factors and  C/EBP. These factors bind independently to their 
corresponding sites, they stimulate apoAI enhancer activity 
synergistically via conjoint recruitment of an uncharacterized 
transcriptional co-activator(s). Apo A1gene transcription is also induced 
by PPARα which interacts with the positive PPRE located in the A site 
of Apo A1 gene promoter liver specific enhancer region. 
The study group included 52 patients who had documented MI, 
and the control group included 52 age, gender and risk factor matched 
groups. Fasting serum levels of TC, TGL, LDL ,HDL, Apo A1, Apo B 
& ratio of Apo B/ Apo A1 were estimated . TC, TGL,LDL level was 
significantly higher in cases compared with controls. Serum HDL, apo 
A1 level was significantly lower in the cases than in the control group 
and that the serum apo B level and apoB/apoA1ratio in the cases was 
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significantly higher than in the control group are consistent with the 
findings of various other studies.
11,19,21,83 
       Polymorphisms at +83 bp and -75bp of the Apo A1 gene have been 
related to elevated levels of HDL cholesterol & ApoA1 in some 
studies
85
, although not confirmed in all studies
86
. 
C+83T(FIRST INTRON) POLYMORPHISM: 
The comparison of genotypes across the cases and controls 
reveals that „TT‟ homozygous genotype was higher among cases and 
„CC‟ genotype was seen more in controls, CT more or less equal among 
cases and controls. Genotype difference between cases and controls 
were statistically significant (p - 0.006).  As far as frequency, „T‟ allele 
was higher among cases (0.36) as compared to controls (0.13); and 
frequency of „C‟ allele was higher among controls (0.86) as compared to 
cases (0.63). Such findings were in concordance with studies conducted 
in Indian populations
82,,87,88
 and from other subjects
86,95
 where the „T‟ 
allele was found to be higher in frequency among CAD population .This 
study is in discordance to some previously reported data particularly 
studies carried out in kashmiris,
89
 Australian populations
81
. In CC 
genotype high mean  value of Apo A1and low Apo B/Apo A1 ratio as 
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compared to TT genotype. But no statistically significant differences 
were observed between C allele and T allele  carriers for any lipid 
variables other than HDL similar to study conducted in Brazilian 
children
96
. 
 
In this studied group of MI, Single base change at C+ 83T bp of 
TT genotype is more common in cases as compared to controls. The 
mechanism behind the association between the single base substitution 
ie C to T at +83 in the first intron of Apo A1 gene and an elevated HDL 
cholesterol level is yet to be finalised and requires further refinement .
82 
It is suggested that the methylation pattern of the 5ʹ region of the 
APOA1 gene reveals the extent of its expression
75
.In apo A1gene 
expressing tissues, the 5ʹ region of the gene is hypomethylated , ie in  
liver but in non expressing tissues it is heavily methylated. The MspI 
restriction site at +83 bp is found to contain a CpG dinucleotide. CpG 
dinucleotide is known to be methylated in nonexpressing cells but 
undermethylated in cells expressing apo A1.Possibly it could be T 
substitution at this site leads to further demethylation, resulting in
 
 Apo 
A1 gene expression. One more explanation is that the T substitution, in 
the 5ʹ end leader region for APOA1 mRNA influences the translation of 
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APOA1 messenger RNA(mRNA) and this could be important for the 
initiation of translation of mRNA.
 
In this study the discrepancy is due to differences in the genetic 
susceptibility between different ethnic groups. Also, the APOA1 gene 
locus lies in a cluster with CIII and AIV loci, which could be in linkage 
disequilibrium with the APOA1 alleles in some populations but not in 
others. 
G-75A( PROMOTER REGION ) POLYMORPHISM: 
The comparison of genotypes across the cases and control reveals 
that „GG‟ homozygous genotype was higher among cases and „GA‟ 
genotype was seen more in controls, AA more or less equal among cases 
and controls. But the difference was statistically insignificant. As far as 
frequency, „G‟ allele was higher among cases (0.75) as compared to 
controls (0.69); and frequency of „A‟ allele was higher among controls 
(0.30) as compared to cases (0.25). Such findings were in concordance 
with studies conducted in Indian populations
82,,87,88
 and from other 
subjects
86
 where the „A‟ allele was found to be higher in frequency 
among control groups. The allele frequency however was also 
insignificant in those studies. This study is in discordance to some 
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previously reported data particularly studies carried out in kashmiris ,
89
 
Australian populations 
81
and by Reguero et al
86
with high frequency of 
the A allele in subjects younger than50 years with a diagnosed MI
 
In GA genotype mean HDL, Apo A1 were high and low Apo 
B/Apo A1 ratio as compared to GG genotype. But no statistically 
significant differences were observed between G allele and A allele 
carriers for any lipid variables . 
 
The MspI -75(G/A) promoter polymorphism was first recorded by 
Pagani et al.
92
A potential description for the effect of the A allele on apo 
A1 levels suggests that the presence of the A allele at–75 bp from 
transcription start site of the gene increases the transcriptional efficiency 
of the promoter.
91
 
 The allele A possibly would be in linkage disequilibrium with a 
different polymorphic site in the nearby gene,
92
 which in turn might 
impact the HDL levels.  
 The polymorphic site might be in a sequence with the Apo A1 gene 
promoter that regulates its expression in response to hormonal 
stimulation and  by various metabolic signalling pathways
92,57,58
.  
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 The probable mechanism is that it may be  due to decreased stability 
of a DNA-protein complex that inhibits transcription.
82
 The 
nucleotide region between 199 to –40 bpis needed for repression of 
transcription by the binding factor (MWt90 kDa) and  is present in 
all cells that do not express the apo A1 gene other than liver and 
intestine in which the gene is expressed . The nucleotide at the –75 
position of the APOA1 promoter lies in a GC-rich sequence 
(5ʹGCC[A/G]GGG-3ʹ).The transcription of these promoters has been 
shown to be negatively regulated by this GC box. A GC binding 
factor(90-kDa factor) could mediate the repression of transcription 
observed in the G allele. The G to A transition decreases its binding 
affinity to–75 bp position and alleviates the repression of APOA1 
gene transcription. 
 Previous studies have reported the effect of genetic and 
environmental factors on Apo AI and HDL-cholesterol levels, 
however, the gene–environment interactions are still incompletely 
known
93
. 
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SUMMARY 
Study conducted in 52 MI cases and 52 controls to look for the 
association between two MspI restriction sites with the lipid variables 
and MI, shows statistically significant differences between cases and 
controls were obtained, across genotype it is summarised below. 
I. C+83T (FIRST INTRON) : Revealed TT genotype more in cases 
and CC genotype more in controls (p-0.006). In CC genotype mean 
value of HDL and Apo A1 were high and low Apo B/Apo A1 ratio 
as compared to TT genotype . T allele frequency is more in cases 
and C allele more in controls. Difference in the mean for lipid 
variables were obtained between C allele subjects and T allele  
carriers but it was not statistically significant except HDL. 
II. G-75A (PROMOTER) : Revealed GG genotype was more in cases 
and GA genotype more in controls, AA genotype distribution is 
more or less equal between cases and control. No statistically 
significant difference across genotypes were obtained. In GA 
genotype mean value of HDL, Apo A1 were high and low Apo 
B/Apo A1 ratio as compared to GG genotype. G allele  frequency is 
more in cases and A allele more in controls. No statistically 
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significant differences were observed between G allele and A allele 
carriers  for any lipid variables. 
In this study Statistically significant difference could not be obtained 
for both the polymorphic site , other than HDL in C+83T because 
 It is critically important to consider the level of confidence to 
place the accuracy of results. 
 Genetic susceptibility between different ethnic groups. 
 The MspI polymorphisms at two sites could be in linkage 
disequilibrium with each other , or with near by gene or with CIII 
and AIV cluster. 
85
 . 
 The genotype effect on circulating Apo A1 and HDL cholesterol 
levels is modulated by gender, hormonal and various metabolic 
signalling pathways as in DM, diet and environmental factors 
such as smoking 
57,58
. 
 Small population chosen. 
 Frequency of the presence of rare alleles. 
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CONCLUSION 
 In this study T allele is significantly increased in cases compared to 
controls which implies that the presence of T allele present in C+83T 
(first intron) of the Apo A1 gene, might increase the development of 
MI. When compared across the lipid variables , no significant 
difference were obtained other than HDL, since various factors 
influences the Apo A1 gene expression. 
  In this study, no statistically significant differences were obtained 
across genotype as well as lipid variables in G-75A (promoter) 
region of Apo A1 gene for the development of MI. 
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LIMITATIONS 
Limitations of this study are 
 Small sample size .  
 Probable occurrence of linkage disequilibrium of APO AI gene 
with the near by polymorphic site and the gene complex APO 
CIII and APO AIV. 
 Gender, hormonal and various metabolic signalling pathways as 
in DM , diet and environmental factors such as smoking could 
have modulated the genotype effect on circulating Apo A1 and 
HDL for the inheritance of such a complex trait CAD which 
progress to dreadful complication MI. 
 Low frequency of the presence of rare alleles. 
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SCOPE FOR FURTHER STUDY 
 Genotypic differences across different ethnic groups for this two 
polymorphic site has to be established. 
 More studies with larger samples are needed to confirm genotypic 
risk associated with the both the polymorphic sites in the 
development of MI 
 Further research may focus upon the gene – gene interactions and 
gene environmental interactions and its relationship with the 
genotypic variation of Apo A1 gene in patients with MI so as to 
provide efficient preventive measures to genetically susceptible 
population in future. 
 Probable occurrence of linkage disequilibrium of APO AI gene 
with the near by polymorphic site and the gene complex APO 
CIII and APO AIV has to be established. 
 Whole genome sequence analysis is needed to reveal extensive 
level of variation and heterogeneity between individuals and 
populations and genome-wide association studies (GWAS) has to 
be done , as these analyses eliminates biases in the selection of the 
candidate genes.  
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PROFORMA 
  Date: 
Name:                                                        OP/IP No: 
 Age:                                                        Sex : 
 Address:                                       Occupation:    
 Presenting Complaints:                                                             
 Past H/O: 
DM/ HT / AGE AT ONSET OF CAD/  Liver disease /Renal disease 
Treatment H/O:  
STATIN THERAPY / BETA BLOCKERS / ACE INHIBITORS/ 
CALCIUM CHANNEL BLOCKERS / HYPOGLYCEMIC AGENTS  
Previous hospitalization: 
Personal H/O: 
SMOKING  / ALCOHOL INTAKE 
O/E:  
Built -               
Height-  
Pedal edema /Anemia/Clubbing /Lymphadenopathy 
VITALS: 
BP:  
Pulse Rate: 
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SYSTEMIC EXAMINATION : 
 CVS:                                                                        Abdomen :    
 RS :                                                                                   CNS: 
 DIAGNOSIS: 
 INVESTIGATIONS: 
 1.Blood sugar2. Urea3. Creatinine 
4. Fasting lipid profile : 
 Total Cholesterol           
 Triglyceride        
 High Density Cholesterol (HDL-c) 
 Low Density Cholesterol  (LDL-c) 
 Apolipoprotein A1 (Apo A1)  
 Apolipoprotein B100 (Apo B)  
5. Genetic polymorphic studies 
 DNA EXTRACTION 
 GENOMIC DNA AMPLIFICATION  BY PCR  
  2% AGAROSE GEL RUN 
  RESTRICTION DIGESTION OF THE PCR PRODUCT 
 Genotype :GG/GA/AA 
CC/CT/TT 
 
 

MASTER CHART – CASES 
 
 
Sl.No PATIENT NAME AGE GENDER SMOKER 
ALCO 
HOL 
H/O  
CAD HT DM Glu Urea Creat Chol TGL HDL LDL APO A1 APO B 
APO B/APO A G-75A C+83T 
T1 SIVARAJ 43 M Y Y N Y Y 108 23 0.8 174 185 35 117 68 109 1.60 GA CC 
T2 BALAMURUGAN 45 M Y Y N N Y 109 14 1.07 206 129 62 96 88 99 1.13 GA CT 
T3 KARUPPASAMY 50 M Y Y N N Y 139 44 1.9 192 144 55 95 92 104 1.13 GA CC 
T4 HASIBUL 56 M N N N N Y 92 42 0.95 133 169 41 66 113 88 0.78 AA CT 
T5 MILLER 42 M Y Y N N y 317 28 6 216 165 24 101 24 59 2.46 GA CC 
T6 VELU 58 M Y Y N N N 121 26 1.17 220 155 75 122 95 111 1.17 GA CC 
T7 BAHADUR 56 M N N Y N N 100 15 0.81 121 93 44 46 82 71 0.87 GG CC 
T8 VADIVELU 67 M Y N N N N 98 17 0.94 179 130 62 89 115 94 0.82 GG CC 
T9 VANI 42 F N N N Y N 104 18 0.64 198 149 64 109 117 113 0.97 GA CC 
T10 KRISHNAN 51 M N Y N N N 79 40 1.4 178 118 60 85 73 89 1.22 GG CC 
T11 VIJAYAKUMAR 46 M N N Y N N 114 19 1.1 154 142 43 58 73 85 1.16 GA CC 
T12 JOHNY BASHA 52 M N N N N Y 322 41 0.92 309 276 30 84 68 79 1.16 AA CC 
T13 KRISHNAIAH 58 M Y N N N Y 199 39 1.31 419 264 45 97 53 65 1.23 GA CC 
T14 PARANTHAMAN 62 M N N N N Y 246 37 1.48 197 156 51 135 73 109 1.49 GG CC 
T15 PALANIVEL 58 M N N Y N N 61 35 1.18 161 134 71 90 119 101 0.85 GG CC 
T16 MNUISAD ALI 42 M N N N Y N 102 22 1.01 145 210 41 73 29 108 3.72 GG CC 
T17 KOLLAPURI 42 M Y Y N N Y 167 16 0.95 188 132 39 121 70 104 1.49 GG CC 
T18 KUMAR 55 M N N N N Y 157 191 5.79 202 232 43 122 83 143 1.72 GG CC 
T19 ASHOKKUMAR 56 M N N N Y Y 102 37 1.82 184 267 44 70 76 93 1.22 GG CT 
T20 ANBUMANI 57 M N N N N N 63 30 1.07 249 268 46 167 101 136 1.35 GG CC 
T21 ANAND 53 M Y N N N N 84 26 0.98 179 232 40 83 74 113 1.53 GA CC 
T22 SHAHUL HAMEED 62 M N N Y N N 72 28 0.86 210 133 53 130 105 123 1.17 AA CT 
T23 SARASWATHY 59 F N N N N Y 138 31 0.94 315 212 78 202 117 154 1.32 GG TT 
T24 MURUGESAN 60 M N N N Y Y 137 38 1.12 181 153 43 93 97 139 1.43 GA CC 
T26 LOURDASAMY 51 M Y N N Y Y 225 30 0.99 270 141 51 105 90 135 1.50 GA CC 
T25 VENUOPAL 44 M N Y N N Y 264 13 0.9 159 196 59 109 86 88 1.02 GA CC 
T27 RAVINDRANATH 62 M N N N N Y 192 25 2.7 261 129 47 108 81 103 1.27 AA TT 
MASTER CHART – CASES 
 
 
Sl.No PATIENT NAME AGE GENDER SMOKER 
ALCO 
HOL 
H/O  
CAD HT DM Glu Urea Creat Chol TGL HDL LDL APO A1 APO B 
APO B/APO A G-75A C+83T 
T28 PERIASAMY 70 M Y N N N N 117 70 2.46 78 214 24 136 42 59 1.40 GA CC 
T29 RAVI 48 M N Y N N N 55 18 0.99 198 187 44 169 70 108 1.54 GG CC 
T30 GEORGE 61 M N N N Y N 91 14 0.99 160 108 52 115 83 82 0.99 GG TT 
T31 GUNASEKARAN 49 M Y N Y N N 88 21 0.78 77 106 29 42 48 49 1.02 GG CC 
T32 BASHEER AHAMED 57 M N N Y N N 128 16 1.18 187 103 46 131 72 100 1.39 GG CC 
T33 THIRUVENGADAM 59 M N N N N Y 137 21 1.03 225 169 49 155 88 102 1.16 GG CC 
T34 MANGALAKSHMI 70 F N N N Y Y 397 26 1 166 103 54 108 86 87 1.01 GG CC 
T35 ARUMUGAM 47 M N N N Y Y 89 14 2.51 213 149 43 145 104 114 1.10 GA CC 
T36 RAJA 43 M N N N Y N 68 19 0.49 228 100 59 128 102 90 0.88 GG CC 
T37 LAKSHMI 63 F N N N Y N 95 32 1.03 238 126 47 167 85 120 1.41 GG CC 
T38 PRABHU 54 M N Y N N Y 143 16 0.9 202 153 59 134 102 135 1.32 GG TT 
T39 MOORTHY 50 M N Y N N N 78 19 0.78 150 181 53 71 100 62 0.62 GG TT 
T40 PONNIAH 62 M N N N N Y 359 77 2.65 150 139 36 67 69 77 1.12 GG TT 
T41 KARTHIK 41 M Y Y N N N 115 17 0.9 165 159 58 108 97 86 0.89 GA CC 
T42 BHARATHI 62 F N N Y N N 127 22 0.75 182 91 53 186 98 75 0.77 GG TT 
T43 VAIDHEESWARAN 53 M N N N N N 84 15 0.41 233 113 22 103 37 42 1.14 GA TT 
T44 BALAKRISHNAN 59 M Y Y N N N 77 19 1.05 194 130 58 173 84 115 1.37 GA TT 
T45 KATHIRVEL 44 M N N N N Y 152 26 0.83 229 368 35 247 44 133 3.02 GG TT 
T46 IQBAL 52 M N N N Y N 124 15 0.8 204 177 57 153 90 105 1.17 GG TT 
T47 SUBRAMANI 42 M Y Y N N N 100 19 1.01 101 312 55 181 88 93 1.06 GG TT 
T48 GOVARDHAN 62 M Y Y N Y Y 90 24 0.8 249 135 23 37 50 59 1.18 GG TT 
T49 KOTHAWARI 42 F N Y N N N 114 40 0.96 207 165 45 177 73 132 1.81 GG TT 
T50 MOHAMED 71 M N N Y N N 89 14 0.89 236 81 61 130 85 92 1.08 GA TT 
T51 DHANAM 52 F N N N N Y 155 38 0.67 224 67 63 153 85 103 1.21 GG TT 
T52 VENKATESH RAO 54 M N Y N N N 100 32 1.19 170 185 53 173 92 102 1.11 GG TT 
 
MASTER CHART – CONTROLS 
 
 
SLNO PATIENT NAME AGE GENDER SMOKER ALCOHOL H/O CAD HT DM Glu Urea Creat CHO TGL HDL LDL Apo  A Apo B APOB/APOA G-75A C+83T 
C1 ARULMOZHI 57 M N N N N y 243 25 0.71 177 113 56 105 110 82 0.75 GG CC 
C2 KASTHURI RANGAN 58 M Y Y N Y Y 87 22 1.22 152 106 47 98 128 66 0.52 GG CC 
C3 GEETHA 54 F N N N Y N 69 23 0.88 129 120 60 102 155 72 0.46 GA CC 
C4 GANAPATHY 65 M N N N N N 90 17 1.05 175 86 71 66 129 90 0.70 GG CC 
C5 CHANDRA 56 F N N N N N 94 19 0.75 180 103 67 111 126 108 0.86 GA CC 
C6 VASUDEVAN 42 M N N N Y N 75 41 0.97 136 87 61 85 92 64 0.70 AA CC 
C7 ARUL 46 M N Y N N Y 315 30 0.91 133 123 61 104 108 66 0.61 GG CC 
C8 HARIKRISHNAN 42 M N N N N N 76 25 1.03 192 94 63 86 98 92 0.94 GG CC 
C9 SUBRAMANIAN  42 M N N N Y N 75 32 1.04 174 104 65 105 118 85 0.72 GA CC 
C10 MUTHULAKSHMI 68 F N N N Y N 116 41 0.76 175 104 75 108 126 111 0.88 GA CC 
C11 RANI 48 F N N N N Y 190 25 0.99 129 89 73 78 141 99 0.70 GG CC 
C12 RAMESH 45 M N N N N Y 274 30 1.03 221 194 67 104 113 115 1.02 GG CC 
C13 LEELA 65 F N N N N Y 172 24 0.73 170 102 82 104 137 69 0.50 GG CC 
C14 LEELAVATHY 68 F N N N Y Y 65 26 0.96 152 116 58 94 119 98 0.82 GG CC 
C15 NARAYANAN 49 M N N N N N 76 26 0.93 209 118 57 111 116 113 0.97 GG CC 
C16 RAJESHWARI 59 F N N N N N 105 21 1.08 221 118 63 112 126 118 0.94 GA CC 
C17 RAJESH 42 M N N N N y 127 23 0.76 173 154 61 75 134 120 0.90 GG CC 
C18 LAKSHMI 33 F N N N N N 95 17 0.73 165 113 53 113 112 100 0.89 GG CC 
C19 MARIAPPAN 56 M N N N N N 92 21 0.97 125 138 46 56 91 83 0.91 AA CC 
C20 NAGABOOSANAM 40 M N N N N N 72 18 0.97 158 122 54 66 104 84 0.81 GG CC 
C21 KRISHNAMOORTHY 45 M Y N N N N 78 23 0.83 213 135 60 138 119 132 1.11 GG CC 
C22 MITHRAN 40 M N N N N Y 50 29 0.97 97 124 42 53 87 92 1.06 GG CC 
C23 SELVAMANI 42 M Y Y N N N 101 41 0.91 165 150 60 82 122 94 0.77 GG CC 
C24 GNANASAMBANDAM 59 M N N N N N 76 24 1.04 131 84 76 58 125 72 0.58 GA CC 
C25 RAVIBALAN 51 M N N N N N 91 28 1.14 143 109 51 43 106 77 0.73 GG CT 
C26 RAMANI 63 M Y Y N Y y 192 18 0.94 197 195 58 97 112 100 0.89 GG CC 
C27 MURUGANANDHAN 56 M N Y N N N 101 33 1.03 194 85 57 108 104 96 0.92 GG CC 
MASTER CHART – CONTROLS 
 
 
SLNO PATIENT NAME AGE GENDER SMOKER ALCOHOL H/O CAD HT DM Glu Urea Creat CHO TGL HDL LDL Apo  A Apo B APOB/APOA G-75A C+83T 
C28 R.R.PAI 72 M Y N N N Y 30 25 0.78 93 73 71 27 115 56 0.49 GA CC 
C29 RAMANUJAM 56 M N N N Y Y 136 20 0.73 243 83 57 175 95 103 1.08 GG CT 
C30 BALU 49 M N Y N N Y 135 22 0.88 300 128 71 104 91 113 1.24 GA CC 
C31 VAIDHYANATHAN 67 M N N N Y N 99 21 0.96 145 141 72 76 157 94 0.60 GA CC 
C32 KALAISELVAM 50 M N Y N N Y 122 35 1.07 239 190 72 197 124 133 1.07 GA CC 
C33 NAJEEMOHAIDEEN 45 M N N N N Y 272 17 0.74 156 229 57 100 120 110 0.92 GA CC 
C34 JAYACHANDRAN 40 M N N N N N 81 27 0.88 173 187 62 135 106 97 0.92 GA CC 
C35 RAMAMURTHY 74 M N N N N N 114 15 0.43 172 81 71 116 117 67 0.57 GA CC 
C36 RAMALINGAM 46 M N N N N y 235 23 0.91 195 202 41 146 105 85 0.81 GG CC 
C37 ARULALAN 69 M N N N N N 62 22 0.82 128 158 58 95 118 80 0.68 AA CT 
C38 ANBU 50 M N N N N Y 339 17 0.95 151 150 55 97 98 75 0.77 GG CT 
C39 DAVID 55 M N Y N Y Y 263 14 1.27 195 240 61 150 106 89 0.84 GA CC 
C40 BASKARAN 64 M N N N N y 202 19 1.02 158 104 60 104 110 67 0.61 GA CT 
C41 SABARATHINAM 58 M N N N N N 109 14 1.13 195 233 63 141 107 77 0.72 GA CC 
C42 MUTHIAH 42 M N Y N N N 104 15 0.96 158 168 55 106 97 77 0.79 GG CC 
C43 SUBRAMANIAN  66 M N N N N N 88 26 1.01 245 151 87 204 130 89 0.68 GA CC 
C44 SIVA 57 M N N N Y Y 145 18 1.15 237 214 72 175 125 101 0.81 GA CC 
C45 GANESH 49 M N N N N N 95 33 0.92 123 135 32 17 70 32 0.46 GA CT 
C46 GANESAN 60 M Y Y N N N 82 13 1.01 119 100 76 87 115 47 0.41 GA CC 
C47 KABILAN 48 M Y Y N N N 81 15 0.99 161 101 64 96 104 66 0.63 GA TT 
C48 PAKKIRISAMY 68 M Y Y N N N 62 16 1.1 188 77 89 121 131 63 0.48 GA TT 
C48 BALU 65 M Y Y N N N 101 13 1.1 82 62 36 47 64 38 0.59 GA CC 
C50 ELUMALAI 48 M N Y N N N 98 14 0.74 176 101 81 122 126 53 0.42 GA TT 
C51 JAGAL 43 M Y N N N y 128 13 0.69 177 82 115 142 141 52 0.37 GA TT 
C52 VIJAYAN 55 M N N N N N 117 16 1.01 110 127 58 33 99 31 0.31 GA CC 
                                                                
BIBLIOGRAPHY 
1. Karathanasis SK, McPheroson J, Zannis VI, Breslow JL. Linkage 
of human Apolipoprotein AI, CIII and AIV genes. Nature 
1983;304:371-3. 
2. Groenendijk M, Cantor RM, de Bruin TW, Dallinga-Thie GM. 
The ApoAI-CIII-AIV gene cluster. Atherosclerosis 2001;157: 
1-11.  
3. Ordovas JM, Civeira F, Genest J Jr et al. Restriction fragment 
length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene 
locus. Relationships with lipids, apolipoproteins, and premature 
coronary artery disease. Atherosclerosis 1991;87:75-86. 
4.  Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU, Faergeman 
O, Humphries SE. Genetic markers in the apo AI-CIII-AIV gene 
cluster for combined hyperlipidemia, hypertriglyceridemia, and 
predisposition to atherosclerosis. Atherosclerosis 1993;100: 
157-69. 
5. Paul-Hayase H, Rosseneu M, Robinson D, Van Bervliet JP, 
Deslypere JP, Humphries SE. Polymorphisms in the 
apolipoprotein (apo) AI-CIII-AIV gene cluster: detection of 
genetic variation determining plasma apo AI, apo CIII and apo 
AIV concentrations. Hum Genet 1992;88:439-46. 
6. Kee F, Amouyel P, Fumeron F. Lack of association between 
genetic variations of apo A-I-C-III-A-IV gene cluster and 
myocardial infarction in a sample of European male: ECTIM 
study. Atherosclerosis 1999;145: 187-95. 
7. Vavatsi NA, Kouidou SA, Geleris PN. Increased frequency of the 
rare PstI allele (P2) in a population of CAD patients in northern 
Greece. ClinGenet 1995;47:22-6.10. Mooradian AD, Haas MJ, 
Wong NC. Transcriptional control 
8. Gordon DJ, Probstfield JL, Garrison RJ, et al. High density 
lipoprotein cholesterol and cardiovascular disease: four 
prospective American studies. Circulation. 1999;79:8-15. 
9. Wilson PW, Abbott RD, Castelli WP. High densitylipoprotein 
cholesterol and mortality: the Framingham Heart Study. 
Arteriosclerosis. 1998;8:737-741. 
10. Ballantyne CM, Hoogeven RC. Role of lipid and lipoprotein 
profiles in risk assessment and therapy. Am Heart J. 
2003;146:227-233 
11. Packard CJ. Apolipoproteins: the new prognostic indicator? Eur 
Heart J Suppl. 2003;5:D9-D16. 
12. Sniderman AD, Furberg CD, Keech A, et al. Apolipoproteins 
versus lipids as indices of coronary risk and as targets for statin 
treatment. Lancet. 2003;361:777-780. 
13. Wallidus G, Junger I. Apolipoprotein B and apolipoprotein A-1: 
risk indicators of coronary heart disease and targets for lipid 
modifying therapy. J Intern Med. 2004;255:188-205.  
14. Curtiss LK, Valenta DT, Hime NJ, et al. What is so special about 
apolipoprotein A1 in reverse cholesterol transport? Arterioscler 
Thromb Vasc Biol. 2006;26:12-19. 
15. Assmann G, von Eckardstein A, Funke H. High density 
lipoprotein, reverse cholesterol transport and CAD: insights from 
mutations. Circulation. 1993;87(4 suppl):III28-III34. 
16. The Joint European Society of Cardiology/American College of 
Cardiology Committee. Myocardial infarction redefined—A 
consensus document of the Joint European Society of 
Cardiology/American College of Cardiology Committee for the 
redefinition of myocardial infarction. Eur Heart J 2000;21:1502–
1513; J Am Coll Cardiol 2000;36:959 –969. 
17. Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF 
Task Force for the Redefinition of Myocardial Infarction. 
Universal definition of myocardial infarction. Eur Heart J 
2007;28:2525–2538; Circulation 2007;116:2634 –2653; J Am 
Coll Cardiol 2007;50:2173–2195. 
18. Thygesen et al. JACC , Expert Consensus Document Month Vol. 
60, No. x, 2012 xxx 
19. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F,  et 
al; INTERHEART Study Investigators. Effect of potentially  
modifiable risk factors associated with myocardial infarction  in 
52 countries (the INTERHEART study): case-control study.  
Lancet 2004; 364 : 937-52  
20. WHO global report 2005 - Preventing chronic diseases: a vital  
investment. Geneva: World Health Organization; 2005.  
21. Vamadevan S. Ajay & Dorairaj Prabhakaran, Coronary heart 
disease in Indians: Implications of the INTERHEART study 
Indian J Med Res 132, November 2010, pp 561-566 
22.  Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk 
factor for cardiovascular disease and a target for lipid-lowering 
therapy–a review of the evidence. J Intern Med. 2006;259:493–
519. [PubMed]  
23. Barter PJ. Hugh Sinclair lecture: the regulation and remodelling 
of HDL by plasma factors. Atheroscler Suppl. 2002;3:39–
47. [PubMed] 
24. Medical biochemistry John W.Baynes –third edition page no:225-
230, Page no:236-240                                                                                     
25. LIPPINCOTT′S illustrated reviews 5 th edition page no:234-236 
26. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241.  
27. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. 
2001;104:503-516. 
28. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-
874. 
29. Suraksha Agrawal and Sarabjit Mastana Genetics of coronary 
heart disease with reference to ApoAI-CIII-AIVgene region 
World J Cardiol.2014 AUG 26;6(8):755-767. 
30. Enas EA, Singh V, Munjal YP, Bhandari S, Yadave RD, 
Manchanda SC. Reducing the burden of coronary artery disease 
in India: challenges and opportunities. Indian Heart J. 
2008;60:161-175. 
31. Coronary Artery Disease (C4D) Genetics Consortium.A genome-
wide association study in Europeans and South Asians identifies 
five new loci for coronary artery disease. Nat Genet. 
2011;43:339-344 
32. Eichenbaum-Voline S, Olivier M, Jones EL, Naoumova RP, 
Jones B, Gau B, Patel HN, Seed M, Betteridge DJ, Galton DJ. 
Linkage and association between distinct variants of the 
APOA1/C3/A4/A5 gene cluster and familial combined 
hyperlipidemia. Arterioscler Thromb Vasc Biol. 2004;24:167-174 
33. Chien KL, Chen MF, Hsu HC, Su TC, Chang WT, Lee CM, Lee 
YT. Genetic association study of APOA1/C3/A4/A5 gene cluster 
and haplotypes on triglyceride and HDL cholesterol in a 
community-based population. Clin Chim Acta. 2008;388:78-83 
34. Delgado-Lista J, Perez-Jimenez F, Ruano J, Perez-Martinez P, 
Fuentes F, Criado-Garcia J, Parnell LD, Garcia-Rios A, Ordovas 
JM, Lopez-Miranda J. Effects of variations in the 
APOA1/C3/A4/A5 gene cluster on different parameters of 
postprandial lipid metabolism in healthy young men. J Lipid Res. 
2010;51:63-73 
35. Yin RX, Li YY, Lai CQ. Apolipoprotein A1/C3/A5 haplotypes 
and serum lipid levels. Lipids Health Dis. 2011;10:140. 
36. National centre for biotechnology information –glossary 
37. ROBIN’S Textbook of Pathology Chapter 11 pg no: 484-488 
38. Kawahiri M, Maugeais C, Rader D: High-density lipoprotein 
metabolism: molecular targets for new therapies for 
atherosclerosis. Curr Atheroscler Rep2 :363 –372,2000 
39. SoTiRios K. KARATHANASIS, VASSILIS I. ZANNIS, AND 
JAN L. BRESLOW Isolation and characterization of the human 
apolipoprotein A-I. gene (preproapolipoprotein A-
I/apolipoprotein gene evolution/lipoprotein/rapid M13 replicative 
form preparation) Natl. Acad. Sci. USA Vol. 80, pp. 6147-6151, 
October 1983 Biochemistry 
40. Oram, J. F., Albers, J. J., Cheung, M. C. & Bierman, E. L. (1981) 
J. Biol. Chem. 256, 8348-8356. 
41. Barker, W C. & Dayhoff, M. 0. (1977) Comp. Biochem. Physiol. 
B57, 309-315 
42. Atherosclerosis, hypertension and diabetes chapter 4 
43. Vu-Dac N, Gervois P, Torra IP, Fruchart JC, Kosykh V, Kooistra 
T, Princen HM, Dallongeville J, Staels B.Retinoids increase 
human apo C-III expression at the transcriptional level via the 
retinoid X receptor. Contribution to the hypertriglyceridemic 
action of retinoids.J Clin Invest. 1998 Aug 1;102(3):625-32. 
44. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart 
JC, Staels B, Auwerx J. Fibrates increase human apolipoprotein 
A-II expression through activation of the peroxisome proliferator-
activated receptor.J Clin Invest. 1995 Aug;96(2):741-50. 
45. Vu-Dac N, Schoonjans K, Laine B, Fruchart JC, Auwerx J, Staels 
B. Negative regulation of the human apolipoprotein A-I promoter 
by fibrates can be attenuated by the interaction of the peroxisome 
proliferator-activated receptor with its response element.J Biol 
Chem. 1994 Dec 9;269(49):31012-8. 
46. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. 
PPAR-gamma dependent and independent effects on 
macrophage-gene expression in lipid metabolism and 
inflammation. Nat Med. 2001 Jan;7(1):48-52 
47. Bowen NJ, Fujita N, Kajita M, Wade, PA. Mi-2/NuRD: Multiple 
complexes for many purposes. Biochimica Et Biophysica Acta, 
1677(1-3), 200452-57. 
48. The expression of the human apolipoprotein genes and their 
regulation by PPARs 
49. XueY, Wong J, Moreno GT, Young MK,Cote J,Wang W. NURD, 
a novel complex with both ATP-dependent chromatin-remodeling 
and histone deacetylase activities. Molecular Cell, 2(6), 1998, 
851-861. 
50. Glass CK, Rosenfeld MG. The coregulator exchange in 
transcriptional functions of nuclear receptors. Genes Dev. 2000 
Jan 15;14(2):121-41. 
51. Lewis BA,ReinbergD. The mediator coactivator complex: 
Functional and physical roles in transcriptional regulation. Journal 
of Cell Science, 116(Pt 18), 2003, 3667-3675 
52. Miller GJ, Miller NE. Plasma high density lipoprotein 
concentration and development of ischaemic heart disease. 
Lancet. 1975;1:16–19 
53. Folkertsma S, van Noort P, Van Durme J, Joosten HJ, Bettler E, 
Fleuren W, Oliveira L, Horn F, de Vlieg J, Vriend G. A family-
based approach reveals the function of residues in the nuclear 
receptor ligand-binding domain. J Mol Biol. 2004 Aug 
6;341(2):321-35 
54. Shaffer PL, Gewirth DT. Structural basis of VDR-DNA 
interactions on direct repeat response elements.EMBO J. 2002 
May 1;21(9):2242-52 
55. Desvergne B, Wahli W. Peroxisome proliferator-activated 
receptors: nuclear control of metabolism. Endocr Rev. 1999 
Oct;20(5):649-88 
56. Arshag D. Mooradian,1 Michael J. Haas,1 and Norman C.W. 
Wong 
57. G M Hargrove, A Junco and N C W Wong Hormonal regulation 
of apolipoprotein AI Journal of Molecular Endocrinology (1999) 
22, 103–111 0952–5041/99/022–10 
58. Douglas C. Harnish, Sohail Malik, EdwardKilbourne, Robert 
Costa and Sotirios K. Karathanasis Control of Apolipoprotein AI 
Gene expression through synergistic interaction between 
Hepatocyte Nuclear Factor 3 and 4J. Biol. Chem. 1996, 
271:13621-13628. 
59. Samson SL, Wong NC: Role of Sp1 in insulin regulation of gene 
expression.J Mol Endocrinol 29:265–279, 2002 
60. Zheng XL, Matsubara S, Diao C, Hollenberg MD, Wong NC: 
Epidermal growth factor induction of apolipoprotein A-I is 
mediated by the Ras-MAP kinase cascade and Sp1. J Biol Chem 
276:13822–13829, 2001 
61. Geofreyy s.ginsforth,josef ozer,sotirios.S.Karanthanasis Intestinal 
Apo A1 gene transcription is regulated by multiple distinct DNA 
elements and is synergistically activated by orphan nuclear 
receptor Hepatocyte Nuclear Factor-4 ,j.clin.inves, volume 96,july 
1995,528-538 
62. Lopez-Candales A: Metabolic syndrome X: a comprehensive 
review of the pathophysiology and recommended therapy. J Med 
32:283–300, 2001 
63. Vajo Z, Terry JG, Brinton EA: Increased intra-abdominal fat may 
lower HDL levels by increasing the fractional catabolic rate of Lp 
A-I in postmenopausal women. Atherosclerosis 160:495–501, 
2002 
64. Duvillard L, Pont F, Florentin E, Gambert P, Verges B: 
Inefficiency of insulin therapy to correct apolipoprotein A-I 
metabolic abnormalities in non-insulin-dependent diabetes 
mellitus. Atherosclerosis 152:229–237,2000 
65. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Jean-Louis 
Chiasson J-L, Garg A, Holzmeister LA, Hoogwerf B, Mayer-
Davis E, Mooradian AD, Purnell JQ, Wheeler M: Evidence-based 
nutrition principles and recommendations for the treatment and 
prevention of diabetes and related complications (Technical 
Review). Diabetes Care 25:148–198, 2002 
66. Elizabeth G. Nabel, M.D., and Eugene Braunwald, M.D. A Tale 
of Coronary Artery Disease and Myocardial Infarction T h e new 
engl and journal o f medicine N Engl J Med 2012;366:54-63. 
67. Godfrey S Getz Catherine A Reardon Apolipoprotein A-I and A-I 
mimetic peptides:a role in atherosclerosis Journal of Inflammation 
Research 2011:4 
68. Carla cuthbert,zhiwei wang,Xia zhang and shui pang Tam                     
Regulation of Human Apolipoprotein A-I Gene Expression by 
Gramoxone J. Biol. Chem. 1997 272: 14954-14960. 
doi:10.1074/jbc.272.23.14954 
69. Ajees, A. A., Anantharamaiah, G. M., Mishra, V. K., Hussain, M. 
M., Murthy, H. M. K. Crystal structure of human apolipoprotein 
A-I: insights into its protective effect against cardiovascular 
diseases. Proc. Nat. Acad. Sci. 103: 2126-2131, 2006 
70. Fryirs MA, Barter PJ, Appavoo M, et al. Effects of high-density 
lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler 
Thromb Vasc Biol. 2010;30:1642–1628. 
71. W.Seandavidson& thomas . R.Thompson The Structure of 
Apolipoprotein A-I in High Density LipoproteinsAugust 3, 2007 
The Journal of Biological Chemistry, 282, 22249-22253. 
72. Philippe G.Frank , yves.v.marcel Apolipoprotein A-I: structure–
function relationships June 2000 The Journal of Lipid Research, 
41, 853-872. 
73. A. Abdul Ajees*, G. M. Anantharamaiah†, Vinod K. Mishra†, M. 
Mahmood Hussain‡, and H. M. Krishna Murthy*§ Crystal 
structure of human apolipoprotein A-I:Insights into its protective 
effect againstcardiovascular diseases  
74. Ruth Shemer, Annemarie Walsh+, Shlomo Eisenbergf, Jan L. 
BreslowS, and Aharon RazinY Tissue-specific Methylation 
Patterns and Expression of the Human Apolipoprotein AI Gene*  
THE JOURNAL. OF BIOLOGICAL. CHEMISTRY    Vol. 265, 
No. 2, Issue of January 15, pp. lOlO-1015,199O 
75. Dmitri sviridov, Anh Hoang,Wei Huang and Jun SASA Structure-
function studies of apoA-I variants site-directed mutagenesis and 
natural mutations 
76. Xi-Long Zheng, Shuji Matsubara, Catherine Diao, Morley D. 
Hollenberg and Norman C. W. Wong Activation of 
Apolipoprotein AI Gene Expression by Protein Kinase A and 
Kinase C through Transcription Factor, Sp1 J. Biol. Chem. 2000, 
275:31747-31754. 
77. Nicole Y. Tan and Levon M. Khachigian Sp1 Phosphorylation and 
Its Regulation of Gene Transcription. molecular and cellular 
biology,may 2009 ,page 2483-2488 
78. Philip J. Barter, H. Bryan Brewer Jr, M. John Chapman, Charles 
H. Hennekens, Daniel J. Rader,Alan R. TallCholesteryl Ester 
Transfer ProteinA Novel Target for Raising HDL and Inhibiting 
Atherosclerosis 
79. Beneficial Effects of Fibrates on Apolipoprotein A-I Metabolism 
Occur Independently of Any Peroxisome Proliferative Response 
Nathalie Hennuyer, BS; Philippe Poulain, BS;  ,Lise Madsen, 
BS;, Rolf K. Berge, PhD; Louis-Marie Houdebine, PhD; Didier 
Branellec, PhD; Jean-Charles Fruchart, PhD; Catherine Fiévet, 
PhD; Nicolas Duverger, PhD; Bart Staels, PhD 
80. X.L. Wang, S.-X. Liu, R.M. McCredie, and D.E.L. Wilcken    
Polymorphisms at the 5’End of the Apolipoprotein AI Gene and 
Severity of Coronary Artery Disease Volume 98, Number 2, July 
1996, 372–377 
81. Rajni Dawar, MD,1 Anil Gurtoo, MD,2 and Ritu Singh, MD1 
Apolipoprotein A1 Gene Polymorphism (G–75A and C+83T) in 
Patients With Myocardial Infarction A Pilot Study in a North 
Indian Population Am J Clin Pathol 2010;134:249-255  
82. Packard CJ. Apolipoproteins: the new prognostic indicator? Eur 
Heart J Suppl. 2003;5:D9-D16 
83. Luciana Moreira Lima; Maria das Graças Carvalho; Marinez 
Oliveira Sousa Apo B/apo A1ratio and cardiovascular risk 
prediction Arq. Bras. Cardiol. vol.88 no.6 São Paulo June 2007 
84. Smith JD, Brinton EA, Breslow JL. Polymorphism in the human 
apolipoprotein AI gene promoter region: association of the minor 
allele with decreased production rate in vivo and promoter 
activity in vitro. J Clin Invest. 1992;89:1796-1800. 
85. Reguero JR, Cubero GI, Batalia A. Apolipoprotein A1 gene 
polymorphism and risk of early coronary disease. 
Cardiology.1998;90:231-235 
86. Padmaja, M.R. Kumar, C. Adithan. ―Association of 
polymorphisms in apolipoprotein A1 and apolipoprotein B genes 
with lipid profile in Tamilian population.‖ Indian Heart J., vol. 61, 
pp. 51-54, 2009.  
87. S. Chhabra, R. Narang, R. Lakshmy, N. Das. ―APOA1-75 G to A 
substitution associated with severe forms of CAD, lower levels of 
HDL and apo-A1 among northern Indians.‖ Dis Markers, vol. 21, 
pp. 169-74, 2005 
88. Tanzeela Khana, Falak Qazib, Sabha Rasoolc, Samia Rashidd, 
Qulsum Akhtare, Akbar Masoodf and Bashir Ahmad Ganaig*  
Genetic Variants at the Apo-A1 Gene in Association with 
Coronary Artery Disease International Journal of Sciences: Basic 
and Applied Research (IJSBAR) (2012)Volume 5, No 1, pp33-42  
89. Wang XL, Badenhop R, Humphrey K, et al. New MspI 
polymorphism at +83 bp of the human apolipoprotein A1gene: 
association with increased circulating high density lipoprotein 
cholesterol levels. Genet Epidemiol. 1996;13:1-10. 
90. Angotti E, Mele E, Costanzo F, et al. A polymorphism(G-A 
transition) in the –78 position of the apolipoprotein A-I promoter 
increases transcription efficiency. J Biol Chem.1994;26:17371-
17374. 
91. F. Pagani,' A. Sidoli,* G. A. Giudici, L. Barenghi, C. Vergani,t 
and F. E. Baralle.Human apolipoprotein A-I gene promoter 
polymorphism: association withhyperalpha1ipoproteinemia  
Journal of Lipid Research Volume 31, 1990 
92. Bahar toptas, uzay gormuş, arzu ergen1, hakan gurkan, fatih 
keleşoğlu,feyza darendeliler, firdevs bas, altay burak dalan, guldal 
izbirak and turgay isbirComparison of Lipid Profiles with APOA1 
MspI Polymorphism in Obese Children with Hyperlipidemiain 
vivo 25: 425-430 (2011) 
93. National health statistics provided by Member States), or the 
latest GlobalBurden of Disease: 2004 Update data (also based on 
WHO country data) (2008a) 
94. ARTO PULKKINEN, MD ,LAURA VIITANEN, MD,ANU 
KAREINEN, MD,SEPPO LEHTO, MD,MARKKU LAAKSO, 
MDMspI polymorphism at +83 bp in intron 1 of the human 
apolipoprotein A1 gene is associated with elevated levels of HDL 
cholesterol and apolipoprotein A1 in nondiabetic subjects but not 
in type 2 diabetic patients with coronary heart disease. 
DIABETES CARE, VOLUME 23, NUMBER 6, JUNE 2000 
95. E. de França1,J.G.B. Alves2 and M.H. Hutz1 APOA1/C3/A4 
gene cluster variabilityand lipid levels in Brazilian children 
Brazilian Journal of Medical and Biological Research (2005) 38: 
535-541. 
